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Abstract

Implications of NEDD9 on AURKA activity: a biomarker for sensitization and therapeutic
target in solid tumors.

Ryan Joseph Ice

The spread of cancer, known as metastasis, is the major cause of relapse and inability
to cure disease. Invasion of cancer cells into neighboring tissue and to distant sites
allows cancer cells to evade therapeutic agents, due to the low therapeutic penetration
of certain tissues such as the central nervous system, and eliminates the feasibility of
resection; which is why the study of pro-metastatic proteins is of great urgency, one
such protein is NEDD9. NEDD9 is overexpressed in various tumor types and is
correlated with poor prognosis due to a more invasive and metastatic phenotype.
NEDD9 serves as a scaffolding protein at the intersection between cell proliferation,
through activation of mitotic Aurora A kinase (AURKA), and invasion, through regulation
of Src kinase and matrix metalloproteinase 14, MMP14, activity. The overall aim of my
work is to determine the role of NEDD9 in tumorigenesis and its implications on AURKA
activity in tumor cells. AURKA is up regulated in the majority of human cancers, but not
in normal cells making it a promising target for therapeutic interventions. There are
several highly specific AURKA small molecule inhibitors in clinical trials to treat cancer.
Nevertheless, it was unknown how NEDD9 binding to AURKA affects inhibitor efficacy,
AURKA degradation, proliferation, and migration of tumor cells. My current studies have
answered some of these critical questions allowing for further improvements of AURKA
based therapeutics leading to prolonging patient survival. Study one demonstrates that
NEDD9 protects AURKA from degradation and limits the successful application of
AURKA inhibitors leading to greater metastasis. Additionally, we established that the
AURKA inhibitor MLN8237 (Alisertib), currently in Phase III clinical trials to treat
advanced lymphomas, has the ability to eliminate breast cancer metastases. Study two
establishes NEDD9 as a necessary scaffolding protein for invasion of breast cancer
cells by regulating the activity of a key extracellular matrix (ECM) degrading enzymes
such as MMP14 and its inhibitor, TIMP2. Study three illustrates the ability of NEDD9
overexpression to increase MMP dependent mammary gland development and
potentially promote tumorigenesis in a transgenic animal model. Furthermore, study
three details the development of a conditional NEDD9 transgenic mouse strain that can
be utilized for various studies. Finally, study four details the method and feasibility of
utilizing patient derived xenograft models for future AURKA inhibitor testing in the
treatment and prevention of metastatic breast cancer. Taken together, this thesis
illustrates the importance and clinical applications of studying the NEDD9-AURKA
signaling hub in treating tumor metastasis.
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Literature Review
1. AURKA: Cell Cycle Regulator and Oncogene
1.1 AURKA activation and domain structure
Aurora Kinase A, also known as AURKA, is a mitotic serine/threonine kinase activated
by an autophosphorylation at amino acid, threonine 288, near the activation loop of the catalytic
domain. Upon phosphorylating threonine 288, the activity of AURKA dramatically increases
(Walter 2000, Ohashi 2006). The AURKA inactivation is regulated by protein phosphatase type
2a (PP2a) which dephosphorylates and inactivates AURKA (Katayama 2001). Additionally,
AURKA activity is curtailed through proteasome mediated degradation, which will be covered in
later chapters. AURKA belongs to the Aurora family of proteins, consisting of three known
members: Aurora A, Aurora B and C. All Aurora kinases possess a variable amino terminal
domain (N) along with a conserved catalytic domain (Cat) (Fig.1).

Fig. 1 Structure of AURKA. Illustrating the regulatory domain and catalytic
domain (http://atlasgeneticsoncology.org)

Despite the structural similarity, the role of AURKA is distinct from Aurora B and C. The Nterminal domain (aa 1-128) allows AURKA to localize to centrosomes (MTOC-microtubule
organizing centers) and interact with microtubules during mitosis (Giet 2001). The structure of
AURKA is such that the N-terminal domain inhibits the catalytic domain when AURKA is not
bound to AURKA activating proteins (Zhang 2007). Binding partners and activators, such as
NEDD9 and TPX2, allow for the release of autoinhibition, resulting in autophosphorylation of
threonine 288 (Pugacheva 2007, Kufer 2002). Once AURKA is activated, phosphorylation of
serine 51, known as the A-Box, is achieved via autophosphorylation protecting AURKA from
degradation (Littlepage 2002). Finally, active AURKA is targeted then to the centrosome through
microtubule binding were it can function as a mitotic kinase.
1.2 The role of AURKA in the regulation of cell cycle and aneuploidy
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Entry into mitosis, one of the phases of cell cycle, is controlled through the activation of
Cdk1 by forming a complex with CyclinB1 (Gavet 2010). AURKA regulates the formation of this
complex through phosphorylation and activation of cdc25b phosphatase, which removes an
inhibitory phosphorylation from Cdk1 (Horn 2007). Accumulation of AURKA at the centrosome is
required for centrosome maturation and segregation (Wang 2010). After initiation of mitosis and
nuclear envelop break down AURKA is targeted from the centrosome to mitotic spindle through
its association with microtubule binding protein TPX2 (Kufer 2002). Microtubule bound AURKA
continues to phosphorylate multiple targets leading to their loading on to the mitotic spindle thus
orchestrating spindle assembly. By regulating both CyclinB1/Cdk1 complex activity and mitotic
spindle loading, AURKA regulates both early G2/M phase transition and mitosis itself. Absence
of AURKA in normal cells results in G2/M arrest or if cells already passed G2/M, the formation
of a monopolar spindle, inability to separate DNA and lethality (Glover 1995). Similar
phenotypes are also present in knockout embryos of AURKA knockout mice being non-viable
even at day 3.5 due to formation of blastocyst consisting of multinucleated cells leading to
chromosome disarray, and retarded growth (Sasai 2008).
1.3 The function of AURKA in tumorigenesis
Overexpression of AURKA, which is common in most cancers, leads to amplification of
centrosomes and multipolar spindle formation resulting in aneuploidy, due to the miss
segregation of chromosomes during mitosis (Tatsuka, 1998). Under normal circumstances
aneuploidy will lead to apoptosis, controlled cell death; however, in the absence of necessary
cell cycle checkpoints, such as p53, the cancer cell will continue to divide resulting in
chromosome instability. Chromosome instability, a hallmark of many cancers, leads to an
increase in mutation rate and a more aggressive phenotype (Meraldi, 2002). To exacerbate the
phenotype, AURKA has been shown to phosphorylate p53 at serine 215, which inhibits p53
DNA binding and transactivation activity (Liu 2004). Other studies show that AURKA is able to
phosphorylate p53 at serine 315 which targets p53 for degradation by Mdm2 via proteolysis
(Katayama 2004). Overexpression of AURKA will result in a decrease in p53, promoting
chromosome instability. Since p53 is a major cell cycle and DNA damage checkpoint the result
of p53 inhibition is increased resistance to radiotherapy and chemotherapeutic drugs, such as
cisplatin and gamma-radiation, which rely on DNA damage checkpoints to induce apoptosis.
1.4 Expression of AURKA in human cancers
AURKA was first discovered to be a part of an amplified portion of chromosome 20q13
during a colon cancer screen. The levels of both AURKA protein and mRNA are increased in
2

more than 50% of primary colon cancers and are increased in breast and other solid tumors
(Bischoff 1998). Independently, AURKA is seen to be amplified in 12% of primary human breast
tumors (Zhou, 1998). AURKA is an oncogene and when overexpressed AURKA is able to
transform rodent fibroblasts and mouse 3T3 cells (Bischoff 1998, Zhou 1998) stating the
importance of AURKA regulation for normal cell growth. While gene amplification is one
mechanism for increased AURKA mRNA and protein found in some breast, colon, prostate,
neuroblastoma, and cervical cancer tumors increased levels of mRNA are also found
independent of amplification suggesting that there are multiple pathways leading to increased
levels of AURKA (Li 2003, Gritsko 2003, Reichardt 2003). In a survey of pancreatic cancers cell
lines all nine tested and 22 of 38 pancreatic cancer patient tissues had from twice to ten times
the amount of AURKA protein when compared to matching normal tissues (Li 2003). In fact
when tested via immunohistochemical staining, elevated levels of AURKA protein are found in
94% of invasive ductal breast adenocarcinomas; while AURKA is barely detectable in benign
breast lesions (Tanaka 1999).
1.5 The impact of AURKA expression in drug resistance and cancer treatment
An important point for breast cancer treatment is the presence of estrogen and progesterone
receptors in the tumor, as these receptors can be utilized as sites for targeted therapy. When
breast cancer tumors are assessed for AURKA levels they positively correlated with both
advanced stage and loss of estrogen and progesterone receptors. In other words, the more
aggressive and harder to treat tumors had more AURKA present, thus indicating AURKA as a
target for inhibitor therapy in tumors resistant to endocrine therapy (Miyoshi 2001). In other
studies, high AURKA levels are detected in premalignant state tumors which were later resistant
to hormone therapy in a carcinogen induced rat tumor model, suggesting once again that
AURKA is a predictive marker for endocrine resistant phenotypes (Goepfert 2002).
The ability to create resistance to standard therapy is a hallmark of AURKA. High levels
of AURKA not only allow tumor cells to accrue chromosomal abnormalities thereby increasing
mutation rates, but also allow tumor cells to bypass key mitotic spindle checkpoints, thus
making the cells resistant to the chemotherapeutic drugs such as paclitaxel (Anand 2003).
However, the ubiquitousness of AURKA overexpression does allow for combinational therapies
to be attempted and give hope for patients by utilizing AURKA inhibitors. Additionally, the ability
of AURKA to repress the DNA damage checkpoint ability of p53 makes AURKA an important
protein for combinational therapies, due to many chemotherapeutics needing p53 activity to
induce apoptosis. More specific to breast cancer is the finding that familial breast cancers
3

containing BRCA2 mutations have increased levels of AURKA, pointing to a site for targeted
therapy for this very aggressive form of breast cancer (Bodvarsdottir 2007).
1.6 Animal models of AURKA over-expression and cancer
Proving AURKA to be an oncogene, AURKA overexpression is able to induce tumor
formation by 20 months in genetic animal models where AURKA expression is driven by mouse
mammary tumor virus (MMTV) promoter. Even before tumors formed, cells present with
elevated Akt levels, the target of rapamycin, and high nucleated cyclin D1 levels resulting in
increased rates of proliferation. Not surprisingly, the cells also presented with extreme
chromosome abnormalities, and yet did not undergo apoptosis (Wang 2006). Additionally in the
mouse mammary model system, when AURKA is overexpressed proliferation rates increase
dramatically as does the levels of p53, due to chromosome defects. Surprisingly, the presence
of high p53 does not induce apoptosis in these tumor cells. In the background of p53
inactivation, AURKA overexpression in the mammary fat pad is able to induce tumorigenesis at
a faster rate, suggesting p53 pathway activation is overcome through selective adaption (Zhang
2004).
1.7 The role of AURKA in invasion and metastasis
While early detection and targeted therapies have increased the survivability of many
cancers; once invasion from the primary site has occurred survivability of disease greatly
decreases. Early reports show AURKA activity stimulates collagen I induced invasion, migration,
and anchorage independent growth, via RalA phosphorylation. RalA is a member of the Ras
family of proteins and is responsible for the formation of filopodia protrusions and vesicle
trafficking (Wu 2005). AURKA has also been implicated in migration and invasion through its
ability to phosphorylate Akt at serine 473, which leads to greater migration rates (Guan 2007).
AURKA phosphorylates and activates the actin severing factor, cofilin, directly regulating actin
dynamics involved in migration and invasion potential of cancer cells (Wang 2010); therefore,
AURKA targeted therapies could prove efficient against invasive and metastatic cancers.

2. AURKA Inhibitors: A promising therapeutic target
2.1 Rational and Development of AURKA inhibitors
Kinases contain a conserved ATP binding site critical for enzymatic function and share a
similar biochemical mechanism of action. They are considered as a first line for designing
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targeted therapies. By blocking the ATP binding site of a kinase, utilizing molecules that
compete with ATP for binding, one can easily inhibit the enzymatic activity of the kinase. Out of
the three Aurora family members, only AURKA and AURKB regulate the cell cycle and could be
targeted to inhibit division; however, only AURKA expression and activity had been shown to
correlate with survival of cancer patients. High AURKA protein levels are a negative indicator of
survival (Nadler 2008). Inhibition of AURKA more efficiently induces mitotic deficiencies and
apoptosis or senescence than inhibition of AURKB (Warner 2006). Additionally, since AURKA
can repress the DNA damage checkpoint through inactivation of p53 inhibition of AURKA will be
beneficial for many combinational therapies which rely on p53 activity to induce apoptosis.
The first attempt in designing effective AURKA inhibitors occurred once the crystal
structure of AURKA was defined down to 1.9Å (Nowakowski, 2002). The next proof of concept
experiments, utilizing computer modeling and inhibitor docking in silico followed by in vitro
inhibitor kinase assays, proved AURKA to be a druggable target (Mahadevan 2003).
2.2 The efficacy of AURKA inhibitors in vitro and clinical trials
The development of VX-680, tozasertib, a pan Aurora inhibitor, with a Ki of AURKA
0.6nM, AURKB 18nM, and AURKC 4.6nM, demonstrated the first successful clinical application
of Aurora inhibitors. VX-680 shows efficacy in xenograft experiments for leukemia, colon and
pancreatic tumors (Harrington 2004). Next, it was found in primary human and mouse prostate
cancer cells that VX-680 is able to induce apoptosis; additionally, VX-680 is able to increase
apoptosis by two fold when combined with doxorubicin, a chemotherapeutic (Lee 2006).Another
inhibitor of the Aurora family, ZM447439, showed the ability to inhibit chromosome
condensation and microtubule spindle formation; however due to the higher efficacy in targeting
AURKB (Ki= 0.36nM) than AURKA (Ki= 100nM) the inhibitor was unable to induce apoptosis
while increasing aneuploidy (Gadea 2005). Showing promise as a drug target, further modeling
and drug design was performed to target AURKA, introducing the use of tricyclic scaffolds
(Warner 2006, Heron 2006). Building upon this work, a second generation of AURKA inhibitors
was developed: PHA-680632, with an IC50 of 27nM for AURKA and 135nM for AURKB, shows
promise by inducing growth arrest in various tumor line xenografts and a transgenic breast
cancer line. However, the inhibitor was unable to eliminate disease by decreasing tumor burden
(Soncini 2006).
By investigating the mechanism of growth arrest and apoptosis induced by the various
inhibitors one can understand which protein to target, AURKA or AURKB, and what mitotic
checkpoints are needed to induce apoptosis. Looking at multiple cell lines, both with and without
5

p53 and p21, researchers were able to discover that VX-680 induces two types of apoptosis. In
cells containing wild type p53 and p21 cells undergo apoptosis upon entering mitosis, due to
DNA duplication accompanied by a lack of segregation of chromosomes. In cells lacking p53
and/or p21, cells undergo endoreduplication, genome duplication without cytokinesis, to the
extent of being non-viable (Gizatullin 2006). The ability of AURKA inhibitor, PHA-680632, to
induce apoptosis in p53 null cells is further shown in HCT116 colon cancer xenograft
experiments, illustrating the additive effect of AURKA inhibitors when combined with
radiotherapy. The additive effect of AURKA inhibitors is due in part to p53 deficient cells being
selected for when DNA damage agents are utilized (Tao 2007). VX-680 also shows much
greater cytotoxicity than ZM447439, an AURKB specific inhibitor, suggesting that induction of
apoptosis is through AURKA (Tyler 2007). Studies also show that AURKA inhibition in multiple
myeloma cells leads to apoptosis via aneuploidy, with neither IL-6 nor activated Ras pro-survival
pathways protecting the cells from apoptosis (Shi 2007). Further investigation of AURKA
inhibition induced apoptosis, via the AURKA specific inhibitor MLN8054, reveals that the
mechanism of action is not necessarily decreased mitosis but deleterious aneuploidy (Hoar
2007). The next generation variant of MLN8054, MLN8237 (alisertib), is currently in Phase IV
clinical trials for treatment of myeloid lymphoma and melanoma,
2.3 The impact of AURKA binding partners on the efficacy of AURKA Inhibitors
Since AURKA activation is induced through binding partner associations and
autophosphorylation, it would stand to reason that AURKA interactors would influence the
efficacy of inhibitions. Examples of AURKA activators are TPX2, AJUBA, and NEDD9 (Eyers
2003, Hirota 2003, Pugacheva 2007). TPX2, targeting protein for Xklp2, is a mitotic protein
present at the start of the G1/S transition and is degraded at the end of cytokinesis. TPX2 binds
the carboxyl terminus of AURKA in a phosphate-independent manner allowing for a local
conformational change in the activation domain, resulting in both AURKA autophosphorylation
and protection from phosphotases, therefore locking AURKA in its active state (Kufer 2002,
Eyers 2003, Bayliss 2003). More explicitly, through binding TPX2, the glycine rich loop, proximal
to the adenosine triphosphate binding site in the amino acid terminus of AURKA, swings via a
hinge region to protect AURKA from dephosphorylation (Eyers 2005).
Utilizing the known dynamics of TPX2 activation of AURKA, computer modeling of
AURKA, both with and without activator binding, establishes that the hydrophobic pocket
adjacent to the adenosine triphosphate (ATP) binding site, which many inhibitors use to lodge in
the active site, is closed upon TPX2 binding (Anderson 2007). Computer modeling experiments
6

were confirmed by the co-crystal structure of bound AURKA/TPX2/VX-680 down to a resolution
of 2.3 Å. The structure shows the binding of VX-680 to AURKA/TPX2 in a completely novel
manner, via binding of the glycine rich hinge region in the hinge region AURKA (Zhao 2008).
These findings support the claim that AURKA binding partners influence heavily AURKA
inhibitor binding profile, pharmacodynamics, and are areas for further investigation.
Combination therapies utilizing AURKA inhibitors and Src inhibitors show efficacy and
synergistic effects. Both Src and AURKA interact with NEDD9, serving as a point of crosstalk
between the two pathways, pointing to the importance of AURKA interactors as a source for
combination therapy design (Ratushny 2012).
3. NEDD9: The oncogenic scaffolding protein
3.1 Structure, binding partners, and post-translatable modifications of NEDD9
The Crk-Associated Substrate (Cas) family of proteins contains four members:
BCAR1/p130Cas, EfS/Sin1, NEDD9/HEF1/Cas-L, and CASS4/HEPL. Cas proteins function as
scaffolding proteins, serving as a platform for proteins to bind therefore increasing the likelihood
of a reaction taking place. Additionally, the Cas family of proteins serves as a mediators of
signaling through post-translational modifications, such as phosphorylation, leading to a change
in protein binding affinities and conformational changes. Between NEDD9, Neural cell precursor
expressed developmentally down-regulated 9, and p130Cas, p130Cas is ubiquitously
expressed in all tissues and is found localized to focal adhesions within cells; while, NEDD9 is
tissue specific and is found throughout the cell. Both proteins contain four domains: 1) a Src
homology 3 domain (SH3) which is able to bind proline rich regions of neighboring proteins; 2) a
substrate domain, containing multiple tyrosine residues, which upon phosphorylation serve a
docking sites for other proteins; 3) a serine rich region, and 4) a carboxyl terminal domain which
contains the focal adhesion targeting region (Fig.2).

Figure 2. Diagram of NEDD9 domains

Both, NEDD9 and p130Cas are able to be phosphorylated by various kinases, such as Src,
focal adhesion kinase (FAK), and Abl (Law 1996). To further complicate the parsing of roles
7

between p130Cas and NEDD9, the two proteins heterodimerize via a Helix Loop Helix (HLH)
motif in the carboxyl terminal domain of the two proteins (Law 1999).
One way to tease out the role of NEDD9 apart from p130Cas is to look at lymphocytes
which naturally lack p130Cas. In T lymphocytes, NEDD9 is phosphorylated in response to
activation of integrin E1 on the cell surface via direct binding of FAK and NEDD9 (Minegishi
1996, Van Seventer 2001). In addition to activating T cells, NEDD9 plays a role in the B cell
activation cascade. Upon ligands binding B cell antigen receptors (BCR) on the surface of B
cells, NEDD9 is phosphorylated as a part of a signaling cascade ending in the rearrangement of
the actin cytoskeleton promoting division and migration (Manié 1997). NEDD9 also plays a role
in myeloid cell activation by serving as a critical hub for phosphorylation and binding. Upon
myeloid immunoreceptor tyrosine-based activation motif (ITAM) binding on the cell surface, Cbl,
Crkl, and NEDD9 are tyrosine phosphorylated forming a complex leading to Rap1 activation, a
small GTPase, resulting in the loosening of cell adherence junctions (Kyono 1998).
Functioning as a critical scaffolding protein allows NEDD9 to influence a multitude of
signaling pathways. As a result of FAK phosphorylation, in the presence of integrin E1,
phosphorylated NEDD9 levels, increasing activation of such pathways as: Jun N-terminal
protein kinase (JNK), transforming growth factor-beta (TGFE  hypoxia-inducible factors 1 & 2
(HIF), and suppression E-cadherin junctions. In the case of the JNK pathway, phosphorylated
NEDD9 binds to active JNK leading to a further increase in NEDD9 levels in a positive feedback
loop, demonstrating the ability of NEDD9 to regulate JNK dependent apoptosis (Law 2000).
NEDD9 influences the TGFEpathway through sequestering Smad6 and Smad7, negative
regulators of the TGFEpathway (Inamoto 2007). Additionally, NEDD9 functions as a hypoxia
inducible factor, since inactivation of von Hippel-Lindau (VHL) tumor suppressor activates HIF
leading to phosphorylation of NEDD9 (Xu 2010). NEDD9 is also phosphorylated in response to
cells being stimulated by epithelial growth factor (EGF) and heregulin (HRG) leading to MAPK
activation (Nagashima 2008).
As with all phosphorylated events, a phosphatase is needed to negatively regulate the
binding cascade; similar to the mechanism to inactivate AURKA, NEDD9 is dephosphorylation
by PP2A thereby enabling the cell to reset the binding cascade of NEDD9 (Bradbury 2012).
3.2 NEDD9 expression in Human Cancers
To understand the importance of a protein in cancer one can look at how ubiquitously
the protein is found to be up or down regulated in various cancer types. Increased levels of an
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individual protein can be caused through a multitude of mechanisms such as: increased
transcription, decreased degradation, targeting by microRNA, and, in the case of cancer,
increasing the number of copies in the genome.
NEDD9 is found to be upregulated in Philadelphia chromosome positive leukemia,
where NEDD9 functions as a scaffold between oncogenic Bcr/Abl and downstream effectors
Crkl and Cbl (de Jong 1997). By comparing multiple melanoma cell lines, NEDD9 is shown to
be the only gene consistently amplified resulting in overexpression of the protein, leading to
increased invasion and migration of melanocytoes (Kim 2006). Corroborating this finding, in
patient samples (n=19) the NEDD9 locus 6p24 is seen by fluorescence in situ hybridization
(FISH) to be amplified in 57% of melanoma patients (Moore 2008). Additionally, in matching
normal and lung adenocarcinomas samples NEDD9 tumor expression and protein levels are
significantly increased, correlating with tumor stage and grade, leading to poor prognosis
(Chang 2012, Kondo 2012). Similar findings are seen in matching pancreatic ductal
adenocarcinoma samples, increasing amounts of NEDD9 correlate with poor prognosis and
higher grade tumors (Xue 2013). In glioblastoma patient samples, microRNA-145 (miR-145) is
downregulated resulting in an increase in NEDD9 expression correlating to higher grade and
decreased patient survival (Speranza 2012). Taking a closer look at lung adenocarcinomas
NEDD9 correlated with hallmarks of epithelial to mesenchymal transition (EMT), such as
fibronectin, and abnormal E-cadherin and E-catenin expression along with an increase in Ncadherin (Miao 2013). The importance of NEDD9 in carcinogenesis was further demonstrated,
in an oncogene-driven genetic mouse model of mammary tumors (MMTV-PyVmT). The NEDD9
knockout in this model led to a significant delay in cancer initiation, decrease in cancer growth,
overall tumor burden, and metastasis. The cancer cells from tumors produced in these animals
have dramatic decreases in FAK, Src, and Akt activity, along with deficiencies in invasion and
migration (Izumchenko 2009).
3.3 The role of NEDD9 in Invasion & Migration
NEDD9 functions in lymphoblastic cells as a scaffolding protein, allowing for crosstalk
between signaling pathways in response to integrin E1 and T cell receptor (TCR) stimulation
(Kamiguchi 1999), and leading to lymphocytic migration. Binding to extracellular matrixes and
TCR stimuli results in phosphorylation of NEDD9, changing the binding characteristics of the
protein, and thereby inducing migration and invasion (Ohashi 1999). NEDD9 is also important
for the formation of neurite protrusions of neurons (Bargon 2005). In embryonic development,
NEDD9 is essential for neuronal crest cell migration (Aquino 2009). Focal adhesion kinase
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(FAK) serves as the link between surface signaling and NEDD9 phosphorylation. When FAK
binds activated integrins, FAK phosphorylates itself and NEDD9, inducing migration (Van
Seventer 2001). NEDD9 is critical for migration of glioblastoma cells in response to platelet
derived growth factor (PDGF) via NEDD9 localization to focal adhesions. NEDD9 plays such an
important part of the focal adhesion kinase (FAK) cascade that the increase in invasion and
migration due to overexpressed FAK is abrogated when NEDD9 expression is impeded
(Natarajan 2006).
Cells have two classes of movement, mesenchymal and ameboid. Mesenchymal
movement is characterized by well-developed adhesions and matrix degradation through the
formation of ventral actin based protrusions known as invadopodia, allowing the cell to pierce
through basal membranes and other heavily cross-linked extracellular matrixes. Ameboid
movement is characterized by few adhesion points and a matrix contraction (without
degradation) based movement via actin-myosin cytoskeleton dynamics through lightly or noncross-linked extracellular environment. Mesenchymal movement is driven by activation of the
GTPase Rac, while ameboid movement is driven by the GTPase Rho. NEDD9 regulates the
switch between the two types of movement by activating Rac and inhibiting Rho through
downstream effectors (Sanz-Moreno 2008). NEDD9 forms a complex with Rac and DOCK6
thereby activating Rac. Activated Rac inhibits Rho via WAVE2. TGFE, known activator of EMT,
induces mesenchymal movement via upregulation of NEDD9 (Giampieri 2009). Another
mesenchymal promoting factor is vascular endothelial growth factor (VEGF). VEGF induces the
formation of invadopodia in a NEDD9 dependent manner (Lucas 2010).
In addition to functioning directly as a switch between mesenchymal and ameboid
movement, NEDD9 is a known epithelial to mesenchymal transition (EMT) inducer. NEDD9 has
the ability, through Src, to disrupt the localization of E-cadherin to the cell surface and promote
lysosomal degradation of E-cadherin (Tikhmyanova 2011, Kong 2011). E-cadherin is necessary
for epithelial cell-cell junctions. In the absence of proper E-cadherin localization the cell can,
transform into a more invasive mesenchymal-like phenotype resulting in potentially greater
metastasis. Silencing of NEDD9 in low E-cadherin expressing cells results in reduced FAK and
Src phosphorylation and restores epithelial morphology (Sima 2013). Other prominent EMT
transducer proteins, such as Twist, also upregulate NEDD9 expression along with Rac1 and
DOCK3 in order to promote mesenchymal type movement of the cell (Yang 2012).
3.4 The role of NEDD9 in regulation of the Cell Cycle and AURKA.
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While NEDD9 is present during all phases of the cell cycle it is upregulated significantly
during the G2/M transition and early stages of mitosis. During mitosis NEDD9 localizes to the
mitotic spindle poles (centrosomes) and mitotic spindle (Law 1998). At the centrosomes,
NEDD9 binds to and changes the conformation of AURKA, allowing for AURKA to undergo
autophosphorylation and activation. Overexpression of NEDD9 leads to an increase in
centrosome number and multipolar spindles, resulting in an aneuploidy phenotype similar to
AURKA overexpression (Pugacheva 2005). Interestingly, the amoeboid movement promoting
protein, RhoA is necessary for cell rounding during mitosis and RhoA inactivation is necessary
for cytokinesis, the division of cytoplasm. NEDD9 functions to activate RhoA, via the mitotic
guanine exchange factor (GEF) Ect2; therefore, overexpression of NEDD9 could lead to
cytokinetic defects and polyploidy (Dadke 2006).
NEDD9 also functions to regulate the cell cycle by regulating primary cilia. Primary cilia
are found on the apical surface of epithelial cells. The cilium is comprised of microtubules with
the lone centriole of the cell at the base, because of this there is only one cilium per cell. In
preparation for entering the cell cycle, primary cilia must be disassembled. NEDD9, in
conjunction with AURKA, sits at the base of the cilia and promotes microtubule deacetylation
and depolymerization via HDAC6 phosphorylation leading to cilia disassembly and initiation of
mitosis (Pugacheva 2007).
Cells lacking NEDD9 have a similar phenotype as cells with AURKA aberrations. While
in murine spontaneous tumor models eliminating NEDD9 results in decreased invasion and later
onset, the tumors that do develop have delayed mitosis and are hyperaggressive in part
because of increased mutation rates due to mitotic defects. Increased mutation rates during
tumorigenesis, similar to other paradigms such as antibiotic resistance, result in a delay in
growth during the selection phase; however, once populations of cells have been selected the
cells are more aggressive and resistant to treatment (Singh 2010).
3.5 Transcript regulation of NEDD9 expression in normal and tumor cells
Many signaling cascades involve increased transcription of NEDD9 leading to increases
in invasion, migration, proliferation, and induction of EMT. The EMT promoting factor,
TGFEinduces a sixteen fold increase in NEDD9 mRNA levels, resulting in an increase in Src
and FAK activity (Zheng 2002). Increased levels of NEDD9 lead to an increase in TGFE
signaling through a positive feedback loop (Bruna 2012). Another EMT factor that can induce
NEDD9 expression is FoxC1, a member of the Fox family of transcription factors. The ability of
FoxC1 to induce migration and invasion is in part due to the upregulation of NEDD9 (Xia 2013).
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The established EMT inducing Wnt pathway is another cascade resulting in increases in
NEDD9 transcription. Members of the canonical Wnt cascade such as: Wnt, E-catenin, and Dvl2
are all able to increase NEDD9 transcription; conversely, E-catenin knockdown results in
decreased levels of NEDD9 (Li 2011). Upon treatment of cells with Wnt inhibitors NEDD9 levels
drop, reducing invasion and migration of tumor cells independent of Src or FAK activation (Iida
2012).
A second instance where NEDD9 expression is transcriptionaly induced is under hypoxic
conditions. Cells experience hypoxia when the level of oxygen in the surrounding tissue does
not meet the requirements of the cell. Tumors often experience hypoxia when growth outpaces
angiogenesis and under inflammatory conditions. Hypoxia is known to induce EMT and increase
migration and invasion of various tumors. Cyclooxygenase-2 (Cox-2) is activated under
inflammatory conditions. Prostaglandin E(2), a downstream component of the Cox-2 pathway,
induces NEDD9 expression thereby increasing cellular proliferation and migration (Xia 2010).
Hypoxia inducible factor-1D (HIF-1D) is a hypoxia induced transcription factor. NEDD9 is a
direct transcriptional target of HIF-1D, leading to increased migration when HIF-1Dis induced.
Upon NEDD9 depletion HIF-1D is no longer able to induce migration, showing the critical nature
of NEDD9 in this cascade. Interestingly, NEDD9 also enhances the transcriptional activity of
HIF-1Dresulting in a positive feedback loop (Kim 2010). Yet another mechanism of induced
NEDD9 expression in response to hypoxia is via the activation on ribosomal protein S6 kinase
(S6K), which is a part of the mammalian target of rapamycin (mTOR) pathway. The mTOR/S6K
pathway responds to metabolism disturbances, such as limited nutrients. Upon activation, S6K
leads to transcriptional increases in hypoxia response genes, one of which is NEDD9 (Ismail
2012).
4. Regulation of NEDD9 and AURKA through degradation
It is important for the homeostasis of a cell to control the amount of each protein within it.
Coordinated degradation of cell cycle regulated proteins is an example of how cells can
accomplish the intricate balance of protein levels. It is necessary for mitotic proteins to be kept
at low levels by degradation when the cell is not undergoing mitosis and to inhibit degradation
during mitosis. In order to accomplish this task, the cell utilizes recognition subunits coupled to
ubiquitin ligases. Each recognition subunit targets a specific set of proteins, thereby
coordinating protein degradation depending on the cells requirements. Many proteins are
degraded via the ubiquitin pathway, in which proteins are post translationally modified with
ubiquitin molecules which signal to the cell that the proteins are to be degraded and trafficked to
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the proteasome. Proteins that are to be degraded are first bound by recognition subunits of
ubiquitin ligases. Once bound by the full ubiquitin ligase complex, ubiquitin ligases along with
recognition subunits, the protein is labeled with ubiquitin molecules and shuttled to the
proteasome for degradation. By utilizing the same ubiquitin ligase and recognition subunits, cell
cycle proteins are able to be degraded in a coordinated manner, signaling the end of mitosis.
In order to accomplish this coordinated destruction the cell employs the E3 ubiquitin
ligase APC, anaphase promoting complex, and its recognition subunit cdh1. Cdh1 binds to cell
cycle proteins at the end of mitosis and signals for APC to conjugate ubiquitin to the protein,
thereby targeting the mitotic proteins to the proteasome for degradation. By degrading cell cycle
proteins APC plays an important role in stopping proliferation. In a survey of 108 invasive breast
cancers, APC was found to be decreased while mitotic index, histologic, and nuclear grade
increased (Park 2005).
Both AURKA and NEDD9, the focus of this study, are degraded in a cdh1/APC
dependent manner (Honda 2000). AURKA is targeted by cdh1 via the D-Box in the carboxy
terminus and a unique A-Box in the variable amino terminus of the protein (Arlot-Bonnemains
2001, Taguchi 2002). The A-box functions as the main site of cdh1 binding, while the D-box
functions as a second site after A-Box ubiquitination; therefore, allowing AURKA degradation to
be independently regulated from AURKB, which contains only a D-box motif (Castro 2002).
Multiple studies show that gene amplification does not account for the levels of accumulated
AURKA in tumor cells; additional mechanism must be present to create such abundant AURKA
detected in tissue and cell lines (Crane 2005, Klein 2005). Interestingly, phosphorylation of
serine at amino acid position 51 in the A-box completely blocks cdh1 dependent degradation of
AURKA, suggesting that dephosphorylation plays a role in both AURKA inactivation and
degradation (Littlepage 2002, Kitajima 2007). In order to exit the cell cycle cdh1/APC
ubiquitinates AURKA, leading to mitotic exit and cytokinesis. Knockdown of cdh1, via siRNA,
leads to a similar phenotype as non-degradable AURKA mutants, failure of cytokinesis and
aneuploidy (Floyd 2008).
Feedback loops also exist to keep NEDD9 levels in check during non-mitotic phases of
the cell cycle. NEDD9 is targeted for destruction upon TGFEinduction, which was discussed
earlier as a promoter of NEDD9 transcription, via Smad3 interacting with the APC/cdh1
complex. By both being able to induce transcription and increase NEDD9 degradation, TGFE is
able to keep NEDD9 transcription and protein increases transient (Li 2000, Nourry 2004). An
additional mechanism to keep NEDD9 function in check is the ability of PP2A, a phosphatase
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that targets NEDD9, to protect NEDD9 from destruction. The preference to degrade
phosphorylated NEDD9 illustrates how APC/cdh1 functions to keep NEDD9 activity at bay
(Zheng 2006). Interestingly, the phosphorylation site that promotes APC/cdh1 binding is serine
396 not serine 296; indicating AURKA dependent phosphorylation is not a signal for NEDD9
destruction since serine 296 is the major target of AURKA phosphorylation (Hivert 2009).
5. Genetic mouse models of human breast cancer
While tissue culture systems are easy to use they are drastically oversimplified and
artificial, due to the limited ability to reproduce the tumor microenvironment and the adaptation
of the cells to grow on plastic. Genetic mouse models of human breast cancer provide a useful
and informative alternative. There are multiple mammary specific promoters utilized in the field
such as: PRXVHPDPPDU\WXPRUYLUXV 0079 ZKH\DFLGLFSURWHLQ :$3 ȕODFWRJORELQ %/* 
and keratin 14 (K14) (Borowsky 2011).

While the MMTV, WAP, and BLG promoters are

expressed in luminal epithelial cells, the K14 promoter is expressed in the basal cells (Derksen
2006).
Utilizing these promoters one can overexpress an oncogene, a dominant negative tumor
suppressor, or conditionally knockout a tumor suppressor to create mammary specific
tumorigenesis. When tumor suppressors such as p53 are mutated heterogenic tumors develop
with long latency due to accumulation of mutations. Simultaneous p53 and E-cadherin
inactivation results in a phenotype very similar to invasive lobular carcinoma (Alvarez 2006).
The most characterized mouse model system is MMTV-PyVmt, polyoma virus middle T
antigen. PyVmT is used to mimic the over expression of Erbb2, which is found to be
overexpressed in 25% human breast cancers (Lee 2010). PyVmT mimics the heterodimer
Erbb2/Erbb3 in a dimerization and ligand-independent manner. Activation of Src, PP2A, and
PI3K are found in both pathways (Dilworth 2002). Perhaps one of the major characteristics of
this model system is that the tumors generated are very consistent. Tumorigenesis is 100%
penetrant with tumors appearing at 20 weeks of age, with tumors initiated at 4 weeks of age.
Mice often present from multiple foci tumors. Tumors also present with weak, though present,
estrogen receptor signaling (Namba 2005).
Due to the early onset of tumorigenesis in the MMTV-PyVmT model, a good alternative
is the MMTV-Her2 mouse model. Her2/Erbb2 heterodimerizes with other Her family members
and activates the PI3K and MAP kinase pathways. Mice present with tumors between 8 to 12
months when the wild type Her2 is used and 5 to 10 months when the activated mutant form of
the protein, neu, is used. Both neu and Her2 models present with frequent pulmonary
14

metastasis (Muller 1998, Guy 1992). 37% of tumors in the wild type Her2 overexpressing mice
have missense mutations of the p53 gene, suggesting the p53 plays an important role in Her2
induced tumorigenesis (Li 1997).
6. Patient derived xenografts (PDX) as a promising new model for preclinical anticancer drug testing
Orthotopic human tumor xenografts contain distinct advantages over transgenic model
systems since transgenic breast cancer in mice often does neither phenocopy human
metastasis nor human breast cancer pathology. Through utilizing human tumor xenograft one
can manipulate tissue culture cells in order to recapitulate genetic aberrations found in human
tumor samples. Additionally, the inclusion of imaging reporters such as luciferase and RFP
reduces the number of mice needed per study since euthanization is not necessary to measure
tumor volume, burden, or metastasis (Jenkins 2005). Also, through the use of orthotopic human
tumor xenografts, one is able to treat the same tumor with multiple treatments and different
stages of disease.
Until recently, most existing in vivo orthotopic models utilized for preclinical assays of
anticancer drugs were based on a limited number of cell lines; which were previously isolated
from human tumors and selected through culturing before being implanted into immunodeficient
animals. Unfortunately, cell lines do not reflect the heterogeneity of human breast cancer
resulting in a weak correlation between animal study results and clinical results. In the Study 4,
we developed new preclinical models based on engraftment of patient-derived tumor samples
that were directly transplanted into animals. In contrast with cell line-derived xenografts, patienttumor xenografts maintain their cell differentiation, morphology, architecture, and the molecular
signatures of the original patient tumors (DeRose 2011). A higher correlation between drug
response of patient-derived tumor xenografts and corresponding original tumors is expected
allowing further development of more efficacious, individualized tumor therapies.
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Abstract
Aurora A kinase (AURKA) is overexpressed in 96% of human cancers and is considered an
independent marker of poor prognosis. While the majority of tumors have elevated levels of
AURKA protein, few have AURKA gene amplification, implying that posttranscriptional
mechanisms regulating AURKA protein levels are significant. Here, we show that NEDD9, a
known activator of AURKA, is directly involved in AURKA stability. Analysis of a comprehensive
breast cancer tissue microarray revealed a tight correlation between the expression of both
proteins, significantly corresponding with increased prognostic value. A decrease in AURKA,
concomitant with increased ubiquitination and proteasome-dependent degradation, occurs due
to depletion or knockout of NEDD9. Reexpression of wild-type NEDD9 was sufficient to rescue
the observed phenomenon. Binding of NEDD9 to AURKA is critical for AURKA stabilization, as
mutation of S296E was sufficient to disrupt binding and led to reduced AURKA protein levels.
NEDD9 confers AURKA stability by limiting the binding of the cdh1–substrate recognition
subunit of APC/C ubiquitin ligase to AURKA. Depletion of NEDD9 in tumor cells increases
sensitivity to AURKA inhibitors. Combination therapy with NEDD9 short hairpin RNAs and
AURKA inhibitors impairs tumor growth and distant metastasis in mice harboring xenografts of
breast tumors. Collectively, our findings provide rationale for the use of AURKA inhibitors in
treatment of metastatic tumors and predict the sensitivity of the patients to AURKA inhibitors
based on NEDD9 expression.
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Introduction
The serine/threonine kinase, AURKA, is a proto-oncoprotein that is overexpressed in
most cancers (1–3). High AURKA expression is strongly associated with decreased survival and
is an independent prognostic marker (4). AURKA overexpression disrupts the spindle
checkpoint activated by paclitaxel or nocodazole, inducing resistance to these compounds (5).
Inhibition or depletion of AURKA protein may therefore improve the survival of patients resistant
to paclitaxel (5). While 94% of the primary invasive mammary carcinomas have elevated
AURKA protein levels (6), only 13.6% show AURKA gene amplification (1, 3). Thus,
posttranscriptional mechanisms of AURKA stabilization are important in breast cancer.
AURKA is polyubiquitinated by the anaphase-promoting complex/cyclosome (APC/C)
complex and targeted for degradation by the proteasome (7). APC/C-dependent degradation of
AURKA requires cdh1, which acts as a substrate recognition subunit for a number of mitotic
proteins, including Plk1 and cyclin B. Overexpression of cdh1 reduces AURKA levels (8),
whereas cdh1 knockdown or mutation of the AURKA cdh1–binding site results in elevated
AURKA expression (7–9). AURKA is ubiquitinated through the recognition of a carboxyl-terminal
D-box (destruction box) and an amino-terminal A-box, specific for the destruction of AURKA (10,
11). Phosphorylation of AURKA on Ser51 in the A-box inhibits cdh1-APC/C–mediated
ubiquitination and consequent AURKA degradation (9).
Cancer cells express high levels of AURKA independently of a cell cycle, which
suggests that there are additional mechanisms of AURKA stabilization. Recently, a number of
proteins were documented to be involved in the regulation of AURKA stability either by direct
deubiquitination of AURKA (12) or through interference with AURKA ubiquitination by APC/C
(PUM2, TPX2, LIMK2; refs. 13–15.)
NEDD9 is a member of metastatic gene signature identified in breast adenocarcinomas
and melanomas (16–18). NEDD9 is a cytoplasmic docking protein of the CAS family. NEDD9
regulates proliferation directly by binding to and activating AURKA (19). In nontransformed cells,
activation of AURKA by NEDD9 in interphase is tightly controlled by a limited amount of NEDD9
in cytoplasm. Overexpression of NEDD9 leads to the activation of AURKA resulting in
centrosomal amplification and aberrant mitosis (19). NEDD9 undergoes ubiquitination and
proteasomal degradation by APC/C. Like typical APC/C substrates, NEDD9 has D-box motifs
and cdh1 binds to a D-box located within the carboxyl-terminal domain (20, 21).
The strong link between increased AURKA expression and cancer progression has
stimulated development of AURKA inhibitors for cancer therapy. PHA-680632 (22, 23),
MLN8054, and MLN8237 (24, 25) are potent small-molecule inhibitors of AURKA activity. These
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compounds have significant antitumor activity in various animal tumor models with favorable
pharmacokinetics (23). However, clinical trials with MLN8054 as a single agent failed to show
tumor growth inhibition (25, 26). In the present study, using human breast cell lines and
xenografts, we have identified NEDD9 as a critical regulator of AURKA protein stability and
sensitivity to AURKA inhibitors. Depletion of NEDD9 via short hairpin RNAs (shRNA) decreases
AURKA protein, sensitizes tumor cells to AURKA inhibitors, and eliminates metastasis in
xenograft models of breast cancer. Combination therapy using NEDD9 shRNAs and AURKA
inhibitors might prove to be an effective treatment strategy for solid tumors with NEDD9
overexpression.
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Materials and Methods
Plasmids and reagents
shRNAs, siRNAs against human NEDD9, AURKA, and control expressed in pGIPZ or in
doxycycline-inducible pTRIPZ vectors (Thermo Fisher Scientific). Lentiviral particles were
prepared as previously described (26). Wild-type, Ser296Ala-A, S296/298-AA, Ser296Glu-E,
and S296/298-EE cDNAs of murine NEDD9 were subcloned into pLUTZ lentiviral vector under
doxycycline-inducible promoter. pcDNA3.1-myc-Ubiquitin and pcDNA3.1-HA-NEDD9 were used
for uELTXLWLQDWLRQ VWXGLHV ,QGXFWLRQ RI VK51$ RU F'1$ ZDV GRQH E\ DGGLWLRQ RI  ȝJP/
doxycyline.
Cell lines and culture conditions
The cell lines MDA-MB-231, BT-549, BT-20, ZR-75-1, MCF7, and MDA-MB-231-luc-D3H2LN
(MDA-MB-231LN) expressing luciferase (Caliper Life Sciences) were purchased and
authenticated by American Type Culture Collection. After infection (or transfection) of shRNAs
(or siRNAs), cells were selected for puromycin resistance and tested by Western blotting.
Protein stability studies
Approximately 2 ×107 cells were plated; 12 hours later, fresh medium containing cycloheximide
 ȝJP/  RU 0*  ȝPRO/  ZDV DGGHG IRU  KRXUV $W LQGLFDWHG WLPH LQWHUYDOV FHOOV
were lysed in protein Triton-based cell lysis buffer (19) with ubiquitin aldehyde (1– ȝPRO/ 
protease inhibitors (Sigma).
Cell-cycle analysis by flow cytometry
The fluorescence-activated cell-sorting (FACS) analysis was done according to a previously
published protocol (19). Cell-cycle distribution was analyzed by FACSCalibur equipped with Cell
Quest software.
Quantitative real-time PCR
Quantitative PCR (qPCR: ref. 27) was carried out in an ABI 7500 Real-Time PCR Cycler and
analyzed using Applied Biosystems SDS software.
Immunohistochemical analysis
High-density breast cancer tissue microarrays BR2082 (Supplementary Table S1) were
collected with full donor consent. Immunohistochemical (IHC) procedures were done according
to the manufacturer's recommendations (US Biomax Inc.) in duplicates. Manual scoring of
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staining intensity [negative (0), weak (1+), moderate (2+), or strong (3+)], as well as location
and cell types was completed by an independent pathologist from US Biomax, Inc. Each core
was scanned by the Aperio Scanning System at ×20. The total number of positive cells and the
intensity of anti-NEDD9 staining were computed by Aperio ImageScope10.1 software based on
the digital images taken from each core.
Western blot procedure and antibodies
Western blotting procedures were previously described (26). Primary antibodies included antiNEDD9 monoclonal antibody (mAb; 2G9; ref. 19), anti-NEDD9 (p55, custom made using
NEDD9 1–394 aa as an antigen), anti-ȕ-actin mAb, or anti-GAPDH (Sigma); anti-AURKA (BD
Biosciences); anti-AURKA (AurA-N, custom made using 1–126 aa N-terminal fragment of
AURKA), anti-phospho-T288 Aurora A (Cell Signaling); and anti-histone H3, and anti-phosphoSer10 histone H3 and anti-ubiquitin (Millipore, BD Biosciences). Blots were developed by the
HyGLO HRP Detection Reagent (Denville Scientific, Inc.). Bands were digitized and quantified
using a digital electrophoresis documentation and image analysis system (G-box, Syngene
Corp.).
Protein expression, GST pull-down, and immunoprecipitation
In vitro pull-down and immunoprecipitation protocols were previously published (19, 26).
Immunoprecipitation samples were incubated with anti-AURKA (AurA-N) or anti-NEDD9 (p55),
immobilized on the A/G-protein Sepharose or 4B-Glutathione agarose for GST pull-down (G&E
Healthcare Life Sciences) at 4°C, washed and resolved by SDS-PAGE. His-tagged cdh1 protein
(Novus International, Inc.), 50 ng of recombinant AURKA and GST-HEF1 in AURKA buffer were
used in the cdh1 titration pull-down.
Animal studies
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient mice were purchased from the
Jackson Laboratory (stock 5557). Animals were housed in the WVU Animal Facility
(Morgantown, WV) under pathogen-free conditions; protocol approved by the Institutional
Animal Care and Use Committee. Primary tumor and organs with metastases were collected,
processed, and analyzed by the WVU Department of Pathology Tissue Bank Core Facility.
Animal bioluminescence imaging
Mice were injected with luciferase-expressing MDA-MB-231LN cells and imaged weekly for
quantitative evaluation of tumor growth and dissemination. About 150 mg/kg d-luciferin (Caliper
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Life Sciences) was injected into the peritoneum. Images were obtained using the IVIS Lumina-II
Imaging System and Living Image-4.0 software.
1. Mammary fat pad injections: For animal studies, cells were grown, trypsinized,
resuspended in DPBS (1 × 107 cells/mL), and 0.1 mL was injected into the fourth
inguinal mammary gland of female mice 6 to 8 weeks of age and followed by
bioluminescence imaging (BLI) up to 6 weeks.
2. Tail vein injections: Males were intravenously injected with 1 × 105 cells and followed by
BLI once a week for 2 to 3 weeks total. Total radiance of lungs was calculated at each
time point in control and treated animals. Lungs were imaged, fixed in formalin at the
end point of study, and analyzed for number and size of metastases by a pathologist.
Tumor volume measurement
Tumor size was assessed by Vevo2100 Micro-Ultrasound System. A 40 or 50 mHz transducer
was used, depending on the tumor size, and a 3-dimensional image (3D) was acquired with
0.051 mm between images. Using the integrated software, the images were reconstructed to
create a 3D image of the tumor.
AURKA inhibitors application
Cell line studies.
Cells were treated with MLN8054 (0–100 nmol/L) or PHA-680632 (0–400 nmol/L) inhibitors
(Selleckchem) for 2 to 12 hours, disrupted in protein Triton-based cell lysis buffer (19)
processed for Western blotting or immunofluorescence staining.
Xenograft studies.
Compound administration began (i) when primary tumors reached 150 to 200 mm3 in female
mice or (ii) 24 hours postintravenous injection of tumor cells in male mice. MLN8237 is an
improved analog of MLN8054 compound with increased stability suitable for in vivo studies.
MLN8237 was dissolved in 10% 2-hydroxypropyl-b-cyclodextrin, 1% sodium bicarbonate in
water. About 20 mg/kg/dose was administered via oral gavage twice daily for 4 days/week for 2
weeks. MLN8237 was tested against a placebo control consisting of drug vehicle.
Statistical analysis
Unpaired t test, nonlinear regression, or 1- or 2-way ANOVA with Tukey's multiple comparisons
were used for statistical analysis of the results. Experimental values were reported as SEM.
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Differences in mean values were considered significant at P < 0.05. Rates of tumor growth were
established by linear regression of the bioluminescence data with time and cohort membership
as covariates. Statistical calculations were conducted using the GraphPad InStat software
package.
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Results
Increased NEDD9 expression tightly correlates with expression of AURKA protein in
breast cancer.
AURKA and NEDD9 are independently overexpressed in many human cancers (1–3,
16–18). We have previously shown that NEDD9 binds to and activates AURKA in cancer cells
(19), and expression of AURKA alone was found to be an independent prognostic marker of
poor survival. To determine whether the expression of both proteins could facilitate the
diagnosis of certain types or stages of breast cancer, we conducted IHC staining for NEDD9
and AURKA in 120 cases of breast cancer. Cases screened from a tissue microarray consisted
of 4 groups of progressive disease stages: (i) normal tissue, (ii) intraductal carcinoma (IC), (iii)
invasive ductal carcinoma (IDC), and (iv) metastatic IDC (MIDC; Supplementary Table S1).
Representative images of IHC staining for each group are shown in Fig. 1A. Statistical analysis
of staining intensity suggests that NEDD9 and AURKA expression positively correlate. The
lowest expression and intensity of either protein was found in normal tissue, whereas a 10- to
20-fold increase in expression was observed in tumor samples (Fig. 1B). Significant correlation
between NEDD9 and AURKA expression was noted for all 4 evaluated tissue types (Fig. 1C).
The Spearman correlation coefficients for the normal, IC, IDC, and MIDC groups are 0.85, 0.67,
0.63, and 0.59, respectively, indicating a positive correlation (Fig. 1C). A random forest fit of
NEDD9 and AURKA positivity staining, which achieved an out-of-bag error rate of 0.508,
indicates that by using NEDD9 and AURKA positivity scores, one can double the predictive
power over chance (Fig. 1D). To define the molecular mechanisms underlying NEDD9 and
AURKA correlative expression profiles, we used a panel of human breast cancer cell lines
where the levels of NEDD9 can be manipulated and controlled.

Depletion of NEDD9 leads to dramatic decrease of AURKA protein in cells lines and
animal models
The expression profiles of AURKA and NEDD9 in a panel of human breast cancer cell
lines followed a pattern similar to that observed in the tissue microarray analysis. Invasive MDAMB-231 (or highly invasive lymph node–derived MDA-MB-231LN), MDA-MB-453, and ZR-75-1
cell lines had the highest levels of expression of NEDD9 and AURKA, followed by BT-549, and
noninvasive MCF7 and BT-20 lines (Fig. 2A). We next evaluated AURKA protein levels in
mouse embryonic fibroblasts derived from NEDD9 knockout (KO) and wild-type (WT) animals.
AURKA expression levels were reduced in KO cells compared with WT cells (Fig. 2B). Similar
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results were obtained by IHC analysis of tissue sections (Fig. 2C), suggesting that maximal
expression of AURKA is dependent on NEDD9.
Depletion of NEDD9 by 2 different shRNAs or siRNAs reduced the levels of AURKA
protein by 60% to 80% (Fig. 2D; Supplementary Fig. S1A). To determine whether the reduced
levels of AURKA were due to transcriptional mechanisms or nonspecific siRNA depletion, we
carried out qRT-PCR analysis for NEDD9 and AURKA. The NEDD9-targeting siRNAs did not
affect the levels of AURKA mRNA (Supplementary Fig. S1B), indicating that NEDD9 regulates
AURKA at the protein level. Moreover, we were able to restore AURKA protein levels in
shNEDD9 cells via re-expression of doxycycline-inducible WT-NEDD9 cDNA (Fig. 2E).
Protein levels of NEDD9 and AURKA are tightly regulated during the cell cycle (28);
therefore, we examined the effects of NEDD9 depletion on the cell cycle. FACS analysis of cells
treated with siRNA targeting NEDD9 did not show significant difference in cell-cycle distribution
when compared with siCon (Supplementary Fig. S1C). These results indicate that the decrease
in AURKA protein level is NEDD9-dependent and is post-transcriptionally regulated.
NEDD9 regulates the stability of AURKA
To further evaluate how NEDD9 governs AURKA expression, we examined AURKA
levels in shCon- and shNEDD9-MDA-MB-231LN cells treated with the protein synthesis inhibitor
cycloheximide. Cycloheximide treatment led to an abrupt decrease in the amount of AURKA in
shNEDD9 cells during the first 3 hours (Fig. 3A). shCon cells had elevated AURKA levels for 6
hours and followed NEDD9 protein decay dynamics (Fig. 3A). The half-life of AURKA was 6 and
3 hours in shCon and shNEDD9, respectively (Fig. 3B). The delayed decrease in AURKA
protein levels in control cells compared with shNEDD9 indicates that AURKA protein stability is
dependent on NEDD9.
Decreased AURKA protein in NEDD9-deficient cells is caused by enhanced proteasomedependent degradation
NEDD9 and AURKA undergo ubiquitination and proteasomal degradation in a cellcycle–dependent manner (9, 20). To test whether the decrease in AURKA protein levels is
associated with increased proteasome-based degradation, cell lines with depleted NEDD9 were
treated with the proteasome inhibitor MG132 (Fig. 3C). Inhibition of proteasomal activity
restored levels of AURKA in shNEDD9 cells to that of control cells (Fig. 3C and D), suggesting
that NEDD9 protects AURKA from ubiquitination- and proteasome-dependent degradation. To
directly test this, AURKA was immunoprecipitated from shNEDD9 and control cells and
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analyzed by immunoblotting with anti-AURKA and antiubiquitin antibodies. Depletion of NEDD9
increased the amount of ubiquitinated AURKA (Fig. 3E and F). Similar results were obtained
with original MDA-MB-231 cells. Moreover, reexpression of wild-type NEDD9 was able to
rescue this phenotype and decrease ubiquitination of AURKA (Supplementary Fig. S1E and
S1F). NEDD9-dependent decrease in AURKA ubiquitination could be caused by steric
hindrance of bound NEDD9 or by titration of ubiquitination machinery components, as both
proteins use the APC/C–cdh1 complex (8, 20). To distinguish between these 2 possibilities, the
levels of other APC/C–cdh1 targets, including Plk1 and Cdk1, in shNEDD9 cells were evaluated
by immunoblotting. No difference in Plk1 and Cdk1 expression was detected between shNEDD9
and controls cells (Supplementary Fig. S1D), indicating that NEDD9 specifically targets AURKA
and does not affect stability of other APC/C–cdh1 substrates. We have previously shown that
NEDD9 binds to the N-terminal domain of AURKA containing the A-box motif (19), which is
required for cdh1 binding and ubiquitination by APC/C (7, 8). To test this hypothesis, we used
recombinant NEDD9, cdh1, and AURKA in in vitro GST pull-down assay and examined whether
the presence of NEDD9 imposes its inhibitory action on cdh1 directly. We confirmed that
NEDD9 was able to bind AURKA in vitro in the presence of excess cdh1 and titrated cdh1 from
the complex with AURKA in a concentration-dependent manner (Fig. 3G and H). Thus, the
presence of NEDD9 potentially increases AURKA protein levels by protecting AURKA from
binding cdh1 resulting in reduced AURKA ubiquitination and subsequent proteasomal
degradation.
NEDD9 binding to AURKA is necessary for protein stabilization
Phosphorylation of NEDD9 at S296 and S298 by AURKA impedes formation of the
NEDD9/AURKA complex (19). To determine the impact of NEDD9 binding on AURKA protein
levels, individual and dual phosphorylation null S296A-(A), S296A/S298A-(AA) and mimetic
S296E-(E), S296E/S298E-(EE) forms of NEDD9 were generated. Indicated mutants were
transfected in HEK293T cells followed by immunoprecipitation of AURKA (Fig. 4A).
Immunoprecipitation analysis showed a reduction in binding to AURKA by the NEDD9
phosphomimetic (E, EE) mutants, whereas phosphorylation null (A, AA) NEDD9 mutants
showed increase in AURKA binding (Fig. 4A and B), in agreement with our previously published
observations (19). The increase in binding by phosphorylation-null mutants in this setting is
expected because of overexpression of NEDD9 in HEK293T cells and inability of
AURKA/NEDD9-AA complex to dissociate. To test the ability of these mutants to rescue the
levels of AURKA in shNEDD9 cells, the 2 NEDD9 mutants (AA, EE) were overexpressed in an
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inducible manner and AURKA levels were measured by Western blotting (Fig. 4C and D).
Reexpression of the AA mutant was sufficient to restore the levels of AURKA protein,
meanwhile, the EE mutant failed to restore the levels of AURKA to control levels due to its
inability to bind AURKA. Therefore, binding of NEDD9 to AURKA is necessary to stabilize
AURKA.
NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro and in in
vivo xenografts
Because of the structural proximity of the ATP-binding pocket to the NEDD9-binding
domain on AURKA (23), we hypothesized that NEDD9-AURKA binding could potentially
interfere with binding of AURKA inhibitors, in addition to preventing cdh1 binding. MLN8054 and
PHA-680632 are ATP-competitive AURKA inhibitors that are currently in phase II clinical trials
that have shown some efficacy against hematopoietic malignancies but have minimal effects
against solid tumors (29–31). To evaluate the impact of NEDD9 expression on therapeutic
outcome, NEDD9 was knocked down in breast cancer cell lines with high NEDD9 expression
before treatment with PHA-680632 or MLN8054. NEDD9 depletion increased the efficacy of
both inhibitors (Fig. 5A), decreasing the IC50 of PHA-680632 from 150 nmol/L in control cells to
50 to 100 nmol/L in shNEDD9 cells (Fig. 5B), as determined by the amount of active phT288AURKA. Similar results were obtained with MLN8054, where the IC50 value decreased from
200 nmol/L (shCon) to 20 nmol/L (shNEDD9; Fig. 5C and D). Inhibition of AURKA function was
further confirmed by analysis of histone H3 phosphorylation in treated shCon and shNEDD9
cells. Inhibition of AURKA leads to accumulation of cells in mitosis characterized by
phosphorylation of histone H3 at Ser10 (Fig. 5B and D and Supplementary Fig. S2E). The
concentration of PHA-680632 was limited to 400 nmol/L to avoid targeting AURKB, which might
lead to decrease in phosphorylation of histone H3.
NEDD9 depletion alone or in combination with AURKA inhibitors reduces tumor burden
and lung metastasis
To examine the validity of our findings in in vivo xenograft models of human breast
cancer, we used MDA-MB-231LN cells and shRNAs targeting NEDD9 or control. Tumor cells
were injected into the mammary fat pad of NSG female mice and the tumor growth was
assessed using BLI (Fig. 6A and B). The original MDA-MB-231LN cell line was tested and
showed similar NEDD9 expression, tumor growth, and metastasis kinetics when compared with
MDA-MB-231LN-shCon cells (Fig. 6A and B and Supplementary Fig. S1F). On the basis of
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these results, we have concluded that the MDA-MB-231LN-shCon cell line is a proper control
and we used it in the subsequent experiments. Depletion of NEDD9 alone reduced tumor
burden by 15% to 20% (Fig. 6B) and reduced the number of metastases in lungs by 25% to
50% (Fig. 6D and E shCon-V, shN2-V and Supplementary Fig. S2A).
Next, we combined shNEDD9 and AURKA inhibitor (MLN8237, a more stable analog of
MLN8054) to test whether the combination will increase the efficacy of MLN8237 against
primary tumor and metastasis (Fig. 6C–E). Treatment was initiated when primary tumor volume
reached 150 to 200 mm3, based on ultrasound measurements in each cohort (30).
Representative images and quantification of tumor volume is shown in Supplementary Fig. S2B
and S2C. Difference in the rates of tumor growth among the 4 groups was assessed by BLI and
pathology measurements using linear regression analysis with time, cell line, and treatment as
covariates. Application of MLN8237 alone did not lead to a decrease in primary tumor growth,
but in combination with shNEDD9, efficacy was improved 2-fold (Fig. 6C). Surprisingly,
treatment with MLN8237 alone significantly decreased the number of lung metastases with a 2fold greater response in shNEDD9-expressing cells (Fig. 6D and E; Supplementary Fig. S2D).
Next, we used intravenous injection of breast cancer cells in NSG male mice to
determine the impact of AURKA inhibitor on colonization by circulating tumor cells. On the basis
of BLI data (Fig. 7A–C) and study endpoint pathology reports on dissected lungs
(Supplementary Fig. S2F), shNEDD9-expressing cells were extremely sensitive to MLN8237
and were not capable of initiating tumor growth in lungs when compared with vehicle-treated
cells. In summary, depletion of NEDD9 sensitizes human xenografted tumors and circulating
tumor cells to AURKA inhibitors and eliminates metastasis to the lungs. Collectively, our data
suggest a model (Fig. 7D) in which overexpression of NEDD9 renders AURKA less susceptible
to Cdh1-APC–mediated ubiquitination and binding of small-molecule ATP-competitive inhibitors,
thus protecting it from degradation and drug applications.
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Discussion
Recent studies corroborate overexpression of NEDD9 specifically with breast cancer
and melanoma metastasis (16–18). Our data indicate that NEDD9 expression levels correlate
positively with oncogenic AURKA expression and activation. Both proteins were correlated with
pathologic parameters in human breast cancer cell lines and breast cancer patient samples.
Moreover, achieving 80% accuracy for predicting cancer stage invasiveness is possible when
screening for expression of both proteins.
AURKA inhibitors have recently entered phase II clinical trials for cancer treatment.
However, the best response achieved in advanced tumors is disease stabilization, as tumor
regression has not been reported (29–32). The knowledge of the molecular factors that
influence AURKA stability and, therefore, sensitivity and resistance to AURKA inhibitors remains
limited. With a few exceptions, such as TPX2 and PUM2 (13, 14), the role of AURKA activators
in the stability of AURKA and their impact on sensitivity to AURKA inhibitors is unknown.
We show here that NEDD9 is a critical component in AURKA activation and stability.
Furthermore, the molecular mechanism by which NEDD9/AURKA signaling functions to
increase breast tumor cell resistance to AURKA inhibitors has been elucidated. Overexpression
of NEDD9 in breast cancer cells prevents proteolytic degradation of AURKA and results in
upregulation of AURKA protein level. AURKA activation correlates with protein stabilization,
which in turn directly depends upon APC/C complex and its substrate recognition subunit, cdh1.
Direct binding of NEDD9 to AURKA hampers the ability of the APC/C complex to ubiquitinate
AURKA by preventing cdh1 binding. A NEDD9-dependent increase in AURKA protein and
activity is critical for G2–M transition. Interestingly, the majority of proteins activating and/or
stabilizing AURKA reside in the nucleus (Bora, TPX2, Ajuba, etc.) or require prior modifications
(TPX2/AURKA binding is stimulated by the GTPase Ran) including phosphorylation by AURKA
for binding (33–36). Nevertheless, a NEDD9-driven increase in the total amount of AURKA
would be less noticeable in mitosis due to the inactivity of cdh1 (8). The excess of NEDD9
protein might promote the binding of known AURKA partners such as Ajuba, TPX2, and Bora
(33, 34) leading to increased loading of AURKA on microtubules and Plk1 activity (37) and
cancer progression. Direct binding of NEDD9 at the N-terminal domain decreases the efficacy of
AURKA inhibitors in cell culture and in mammary tumor xenografts. Deletion or mutation of
NEDD9 dramatically decreases AURKA protein level and kinase activity. Phosphorylation of
NEDD9 by AURKA at Ser296 serves as a negative feedback loop to regulate the levels of active
AURKA. The abundance of NEDD9 in epithelial cancers and dephosphorylation by PP2A (21)
creates a constant supply of unphosphorylated NEDD9 that would stabilize and activate
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AURKA. We found that depletion of NEDD9 reduces tumor cell proliferation and lung
metastases of orthotopic human tumor xenografts. Finally, we have established that treatment
with AURKA inhibitors is particularly efficient against metastasis. In combination with shNEDD9
RNAs, MLN8237 abolishes lung metastases from orthotopic xenograft models as well as in lung
colonization assays. No significant changes in animal weight and no apparent toxicity were
noticed, suggesting a favorable toxicity profile.
The correlation of AURKA and NEDD9 expression in cancer patient biopsies could be
critical for diagnostic purposes. It could potentially be used to predict the sensitivity of these
patients to AURKA inhibitors. In addition, our results advocate the development and
investigation of new NEDD9-targeting compounds as a novel therapeutic strategy against
metastatic breast cancer.
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Figure Legends
Figure 1. Increased NEDD9 expression correlates with expression of AURKA protein in
invasive ductal breast adenocarcinomas. A, representative images of IHC staining of tissue
microarray with anti-AURKA (top) and anti-NEDD9 (bottom) antibodies. Normal breast tissue,
intraductal carcinoma (IC), invasive ductal carcinoma (IDC), metastatic invasive ductal
carcinoma, lymph nodes (MIDC-/1 6FDOHEDUȝP,QVHWVUHSUHVHQWîHQODUJHGDUHDV
indicated in the main panel. B, quantification of NEDD9 and AURKA in relative units of positivity
(RUP; percentage of cells stained positively in the same core stained by anti-AURKA or NEDD9 antibodies). Most fitted lines were plotted on the graphs. C, positivity data for both
proteins were analyzed using Spearman Rho correlation. D, positivity data for both proteins
were analyzed by random forest statistical software.
Figure 2. Depletion of NEDD9 leads to dramatic decrease of AURKA protein. Western blot
analysis of NEDD9 and AURKA in breast cancer cell lines (A) and mouse embryonic fibroblasts
(B) derived from wild-type (WT) and NEDD9 knock out (KO) animals. C, representative IHC of
anti-AURKA staining in kidney tissues, WT, and NEDD9-KO mice. Staining with nonspecific IgG
&RQ 6FDOHEDUȝPD, Western blot analysis and quantification of AURKA, NEDD9, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) upon treatment with anti-NEDD9 (shN1,
shN2) or nonspecific (shCon) shRNAs, n = 3, percentage of AURKA expression to shCon, ±
SEM. Student one-tailed t test: **, P = 0.0006; **, P = 0.0024 (shCon/shN1 or/shN2) and no
significant difference (ns; shN1/shN2) in MCF7. **, P = 0.003; **, P = 0.0094 (shCon/shN1
or/shN2) and ns (shN1/shN2) in MDA-MB-231. E, WB analysis and quantification of AURKA
and NEDD9 expression in shNEDD9 and shCon cells transfected with WT-NEDD9 or controlRFP (red fluorescent protein) cDNA; n = 3, percentage of AURKA expression to shCon,
normalized by GAPDH. Student one-tailed t test: *, P = 0.0186; **, P = 0.0012 (shCon/shN1
or/shN2), ns (shN1/shN2 or shN1/NEDD9 and shN2/NEDD9 reexpression).
Figure 3. NEDD9 regulates stability of AURKA through inhibition of proteasome-dependent
degradation. A, Western blot analysis of AURKA and NEDD9 expression in shCon-, shNEDD9MDA-MB-231LN cells WUHDWHG ZLWK F\FORKH[LPLGH ([SUHVVLRQ ZDV QRUPDOL]HG E\ Į-tubulin. B,
quantification of AURKA as in A, n = 3, fold of change of AURKA expression to time point 0
hours, ±SEM, one-way ANOVA: ***, P < 0.0001; **, P = 0.005 (shCon/shN1 or/shN2) at each
time point (except 0 hour). C, Western blot analysis of AURKA, NEDD9 in shCon, shNEDD9
cells treated with MG132 or vehicle. D, quantification of AURKA expression as in C (+MG132),
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n = 3, fold of change to shCon, ±SEM. Student t test: **, P = 0.0086; **, P = 0.0084
(shCon/shN1 or/shN2). E, Western blot analysis of AURKA ubiquitination in WCL and
immunoprecipitation (IP) from shCon or shNEDD9 cells transfected with pcDNA3-Myc-Ubiquitin,
with MG132. F, quantification of AURKA ubiquitination as in E, IP, n = 3, fold of change to
shCon, ±SEM. Student t test: **, P = 0.0098; *, P = 0.05 (shCon/shN1 or/shN2). G, WB with
anti-AURKA, anti-NEDD9, and anti-cdh1 antibodies. H, quantification of AURKA using the
following formula (AURKA-IP/AURKA-total) normalized to NEDD9 pull-down as in G, n = 3,
plotted as AURKA ratio ± SEM, *, P < 0.05.
Figure 4. NEDD9 binding to AURKA is necessary for protein stabilization. A, Western blot
analysis of AURKA and NEDD9 expression in WCL (left) or IP-GFP (right) from 293T cells
transfected with pAcGFP-NEDD9-WT, AA, EE A, E, mutants, or GFP control. B, quantification
of AURKA-coIP as in A, n = 3, plotted as percentage ± SEM. AURKA-coIP with wtNEDD9
assigned 100%. Student t test: **, P = 0.0013; *, P = 0.010; **, P = 0.00209, ns (WT/AA or/EE
or/A or/E, respectively). C, WB analysis of AURKA and NEDD9 expression in WCL of MDA-MB231 cells expressing doxycycline-inducible NEDD9-AA, -EE, or empty vector control. D,
quantification of AURKA expression as in C, n = 3, relative intensity units (RIU) ± SEM,
normalized to actin. Two-way ANOVA: P < 0.0001. Student t test: **, P = 0.0063, 0.0061 [AA/EE
(+Dox, 24, 48 hours)].
Figure 5. NEDD9 binding to AURKA decreases the efficacy of AURKA inhibitors in vitro. A,
Western blot analysis of AURKA, phT288-AURKA, NEDD9 in shCon or shNEDD9-MDA-MB231LN cells treated with PHA-680632. B, quantification of phT288-AURKA expression as in A, n
= 3, normalized to total AURKA and plotted as relative intensity units (RIU) ± SEM. Two-way
ANOVA: P < 0.0001, (shCon/shN1 or shN2), P = 0.0013 (shN1/shN2). Quantification of phS10Histone H3 (IF), n = 3, 1000 cells/treatment, P = 0.006, P = 0.0067 (shCon/shN1 or shN2), no
significant difference (shN1/shN2; C). Western blot analysis of total AURKA, phT288-AURKA,
NEDD9 expression in cells treated with increasing concentrations of MLN8054. D, quantification
as in B for the Western blots shown in C. P < 0.0001, (shCon/shN1 or shN2), P = 0.0041
(shN1/shN2). Quantification of immunofluorescence shown in Supplementary Fig. S2E, n = 3,
1,000 cells/treatment, P = 0.0053, P = 0.0086 (shCon/shN1 or shN2), no significant difference
(shN1/shN2).
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Figure 6. Depletion of NEDD9 combined with AURKA inhibitors leads to decrease in a tumor
burden and lung metastasis in breast cancer xenograft model. A, representative images of BLI
of mice orthotopically injected with MDA-MB-231LN parental, shCon, or shNEDD9 (shN2) cells.
B, quantification of BLI data as in A plotted as mean log photon flux ± SEM. Linear regression
analysis, P = 0.0021, P = 0.0006 (shCon/shN2), weeks 3 and 4; no significant difference
(shCon/parental). C, quantification of BLI data, mice orthotopically injected with shNEDD9 or
shCon cells and treated with MLN8237 (MLN) or vehicle, 3 independent experiments, n = 6 in
each group; mean photon flux, ± SEM. Two-way ANOVA, P = 0.0061 (shCon-MLN/shN2-MLN,
days 7–11). D, representative images of BLI, lungs dissected from 4 groups. E, quantification of
BLI data as in D, 3 independent experiments, n = 6/group; mean photon flux ± SEM. Two-way
ANOVA: **, P = 0.0071 (shCon-Vehicle/shN2-Vehicle); **, P = 0.045 (shCon-MLN/shN2-MLN).
Figure 7. Combination of AURKA Inhibitors with depletion of NEDD9 reduces colonization
potential of human circulating tumor cells in lungs. A, representative images of BLI; mice
intravenously injected with MDA-MB-231LN cells expressing shCon or shNEDD9 (shN2) and
treated with MLN8237 (M) or vehicle (V). B, quantification of BLI data as in A, 3 independent
experiments, n = 6/group, plotted as fold growth of BLI mean radiance ± SEM. Two-way
ANOVA: P < 0.0001 (shCon-V/shCon-M), (shN2-V/shN2-M), (shCon-V/shN2-V); P = 0.0145
(shCon-M/shN2-M). C, quantification of BLI as in A, dissected lungs; 3 independent
experiments, n = 6/group, mean photon flux ± SEM. One-tailed Student t test: P < 0.0001
(shCon-V/shCon-M), (shN2-V/shN2-M), P = 0.009 (shCon-V/shN2-V), P = 0.0335 (shConM/shN-M). D, model of NEDD9 action on AURKA stability and inhibitors competitive binding
(I/III). Under normal physiologic conditions with low NEDD9 expression, AURKA is not solely
bound to NEDD9 and gets targeted by cdh1 and AURKA inhibitors (II/IV). Overexpression of
NEDD9 leads to sequestering of AURKA by NEDD9 and limits cdh1 binding, thus stabilizing
AURKA and hampers the ability AURKA inhibitors to access ATP pocket.
Supplementary Figure 1. Depletion of NEDD9 with siRNA does not affect transcription or
cell cycle distribution, but decreases AURKA protein levels. (A). Western blot analysis of
AURKA and NEDD9 protein levels in MCF7 cells transfected with siCon or siNEDD9 smart pool.
Quantification of AURKA and NEDD9 proteins is shown on the right panel. (B). Quantitative
PCR analyisis (qPCR) of NEDD9 and AURKA mRNA levels after siRNA treatment and in (A).
One tailed Students t-test of aurka mRNA levels indicates no statistically significant difference
(ns) between siNEDD9 and control, p=0.327 between siCon and siNEDD9. (C). Flow cytometry
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analysis of cell cycle distribution of siNEDD9 and siCon treated cells. (D). Western blot analysis
of NEDD9, CDK1, cyclin B (CKB), PLK1 and actin expression levels in MDA-MB-231 cells
expressing siControl or siNEDD9 (smart pool, 4 siRNAs). (E). WB analysis of NEDD9, AURKA
and ubiquitinated AURKA in MDA-MB-231 cells expressing shCon, shNEDD9 (shN1) and shN1
rescued with exogenouse expression of wt HA-tagged NEDD9 cDNA. (F). WB analysis of
NEDD9, AURKA and GAPDH in MDA-MB-231 and MDA-MB-231LN cells.
Supplementary Figure 2. Combination of AURKA inhibitors with Depletion of NEDD9
dramatically reduces metastasis to lungs. (A). Quantification of number of metastasis in
lungs of orthotopically injected animals at the end of the study. Results were plotted as mean
number of metastases per mm2 +/-S.E.M from 3 independent experiments with n=6 per
treatment group. Two way ANOVA indicated statistically significant difference p=0.048 only for
shCon-M and shN2-M, the rest was ns. (B). Representative images of Vevo200 ultrasound 3D
reconstructed tumors from siNEDD9 (14 days) and siCon (8-10 days) orthotopically injected
mice. Scale bar 1mm. (C). Quantification of tumor volume before application of MLN8237.
Treatment was initiated upon similar volumes were reached in all 4 groups (time point zero for
MLN treatment). One way ANOVA, did not identified any significant difference between the
groups (ns). (D). Quantification of number of metastasis in lungs of intravenously injected
animals at the end of the study of shCon and shNEDD9 (shN2) treated with MLN8237 (MLN) or
vehicle alone at the end of the study. Results were plotted as average number of metastases
per mm2 +/-S.E.M from 3 independent experiments with n=6 per group. Two way ANOVA
indicated statistically significant difference p=0.045 only for shCon-M and shN2-M, the rest was
ns. (E). Representative images of immunofluorescent staining with anti-phSer10-Histone H3
antibodies (magenta), DNA (dapi, cyan) and GIPZ-shRNAs (green) of shCon and shNEDD9
(shN1) MDA-MB-231LN cells. The scale bar is 10
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Abstract
The scaffolding protein NEDD9 is an established pro-metastatic marker in several cancers.
Nevertheless, the molecular mechanisms of NEDD9 driven metastasis in cancers remain ill
defined. Here, using a comprehensive breast cancer (BCa) tissue microarray, it was show that
increased levels of NEDD9 protein significantly correlated with the transition from carcinoma in
situ to invasive carcinoma. Similarly, it was shown that NEDD9 overexpression is a hallmark of
highly invasive BCa cells. Moreover, NEDD9 expression is crucial for the protease-dependent
mesenchymal invasion of cancer cells at the primary site but not at the metastatic site.
Depletion of NEDD9 is sufficient to suppress invasion of tumor cells in vitro and in vivo, leading
to decreased circulating tumor cells (CTCs) and lung metastases in xenograft models.
Mechanistically, NEDD9 localized to invasive pseudopods and was required for local matrix
degradation. Depletion of NEDD9 impaired invasion of cancer cells through inactivation of
membrane-bound matrix metalloproteinase MMP14 by excess TIMP2 on the cell surface.
Inactivation of MMP14 is accompanied by reduced collagenolytic activity of soluble
metalloproteinases MMP2 and MMP9. Re-expression of NEDD9 is sufficient to restore the
activity of MMP14 and the invasive properties of BCa cells in vitro and in vivo. Collectively,
these findings uncover critical steps in NEDD9-dependent invasion of BCa cells. Implications:
This study provides a mechanistic basis for potential therapeutic interventions to prevent
metastasis.
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Introduction
The cytoplasmic docking protein, NEDD9 has emerged as a biomarker of melanoma,
pancreatic, and lung cancer metastasis and is required for the migration of tumor cells (1-6).
The overexpression of NEDD9 leads to mesenchymal protease-dependent migration (4, 7).
NEDD9 promotes epithelial-mesenchymal transition (EMT) and invasion of BCa cells (8).
Extracellular matrix (ECM) proteolysis is dependent upon soluble and membrane bound
matrix metalloproteinases (MMPs) (9). Membrane bound MMP14 is a key enzyme involved in
ECM degradation and invasion of tumor cells. The activity of MMP14 is regulated by
phosphorylation, proteolysis, and endocytosis (10-11). MMP14 is activated by furin and is
inhibited by tissue inhibitor of MMP, TIMP2, which makes a stable complex with the activated
MMP14 (12-13). The tertiary complex of MMP14, TIMP2, and proMMP2 is required to form on
the cell surface to activate MMP2 by a neighboring MMP14 free of TIMP2 (14). The presence of
excess TIMP2 results in inhibition of MMP14 activity and decreased processing of proMMP2 to
active MMP2 (15). In invasive cancer cells, MMP14 is localized at the membrane of
invadopodia, ventral actin-based membrane protrusions (16-17). Local ECM degradation is
initiated upon the assembly of: F-actin, cortactin, N-WASP, and the Arp2/3 complex (17-18).
Functional mature invadopodia form when F-actin and cortactin-rich puncta initiate the
accumulation of MMP14, thus forming proteolytically active protrusions (16). Activity of MMP14
is required for invasion of 3D collagen matrices in tissue culture and in nude mice (19- 20).
While NEDD9 deficient cells are characterized by reduced migration accompanied with
reduced levels of Src and FAK kinase activity (21-22) the role of NEDD9 in the function of
invadopodia in BCa has been unclear. Although NEDD9 and another Cas family member,
p130Cas, were previously identified in invadopodia of cancer cells (23-25), the differences
between NEDD9 and p130Cas function in invasion are currently unknown.
In transgenic oncogene driven mammary tumor models such as MMTV-PyVmT or
MMTV-Her2/Erb2 genetic ablation of NEDD9 leads to delays in tumor initiation and growth but
has a limited effect on metastasis (21-22). The tumors arising in MMTV-Her2/NEDD9-/- or
PyVmT/NEDD9-/- mice underwent a dramatic mutational selection that overcame the initial
requirement for NEDD9. In this context it is difficult to determine the requirement for NEDD9 in
metastasis since the selection of alternative signaling pathways happened prior to tumor
formation. Also, it is currently unknown what stages of metastasis are affected by NEDD9.
Overexpression of NEDD9 is often mentioned in diverse cancers (1-4). However, as of
now, a comprehensive analysis of NEDD9 expression with respect to BCa progression has not
been conducted; To address these questions, we analyzed NEDD9 protein expression in a
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tissue microarray (TMA) consisting of 200 progressive BCa patient biopsies and in a panel of
diverse BCa cell lines. We found that NEDD9 is overexpressed in invasive breast ductal
carcinomas and invasive cell lines. We discovered that NEDD9 is involved in regulation of
MMP14 activity on the cell surface, but not expression. Depletion of NEDD9 leads to decrease
in proteolytic activity of soluble MMPs and transmembrane MMP14, resulting in the ablation of
cancer cell invasion in vitro and in vivo. The decrease in activity was due to the association of
MMP14 with its inhibitor TIMP2 on cell surface. Depletion of TIMP2 or MMP14 expression or
addition of excess of recombinant TIMP2 to control cells led to a similar phenotype, suggesting
that excessive TIMP2 bound to the MMP14 potentially is the primary reason for decreased
invasion in carcinoma cells upon depletion of NEDD9.
Using inducible shRNAs against NEDD9 in xenograft models, we dissected particular
stages of metastasis dependent upon NEDD9 expression and thus define the sensitive stages
of tumor progression where anti-NEDD9 therapy could be applied to prevent metastasis. We
found that reduction of NEDD9 expression in established tumors leads to a drastic decrease in
MMPs activity and number of circulating tumor cells resulting in a decrease in the overall
number and size of pulmonary metastases. Collectively, our findings suggest a novel
mechanism for NEDD9 in accelerating cell invasion through regulation of MMP14 by TIMP2
thus defining the new therapeutic approach for anti-metastatic strategies via manipulation of
NEDD9 expression.
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Materials and methods
Plasmids and cell culture. Cell lines MDA-MB-231, MDA-MB-453, ZR-75-1, BT-549, MCF10A,
MCF7, AU-565, BT-20, were purchased from and authenticated by American Type Culture
Collection (ATCC), MDA-231-LN (Caliper Life Sci.) and grown based on manufacturer’s
recommendations. shRNA expressing constructs against NEDD9, control (sequences available
upon request) and smart pool siRNAs against MMP14 and TIMP2 and siControl were
purchased from ThermoFisher Scientific as ready to use siRNAs or in pGIPZ, or in doxycyclineinducible pTRIPZ vectors. Lentiviral particles were prepared as previously described (26). For
rescue experiments wild type cDNA of mouse NEDD9 was subcloned into pLUTZ lentiviral
vector under doxycycline-inducible promoter (27). Cell medium and supplements were
purchased from ATCC (Sigma).
MMP Antibody Array. MMP Antibody Arrays were purchased from RayBiotech, Inc. and
assays were carried out according to the manufacturer’s protocol using whole cell lysate (WCL)
and conditioned for 24h serum free medium (SFM).
Fluorescent-gelatin degradation assay. Foci of degraded matrix were visible as dark areas
that lack fluorescence in the FITC-gelatin matrix (Life Technologies). Cells with pseudopods
were identified by the presence of at least one actin/cortactin aggregate within the cell.
Degradation per cell area was analyzed using ImageJ (NIH) as described (16). At least 100
cells were counted per each experimental condition. Data were pooled from multiple
independent experiments.
DQ Collagen Assay. Cells expressing doxycycline-inducible shRNAs against NEDD9 and red
fluorescent protein (RFP) embedded in DQcollagen I/IV combined with matrigel (BD
Biosciences) to allow for cell tracing and dose-dependent manipulation of NEDD9 depletion.
shRNA expression was induced for 72h. DQ collagen I/IV/matrigel assays were carried out
according to a previously published protocol (28). Detailed protocol for data acquisition and
analysis outlined in supplementary material.
EnzChek Gellatinase/Collagenese assay. Assay was purchased from Life Technologies and
performed accordingly to manufacturer’s recommendations using shNEDD9 and shCon
conditioned medium (24h). Fluorescence was measured at 485/545mn.
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Gelatin zymography. The gelatin zymography protocol was performed as previously described
(16, 24). Briefly, 4ml of 24h conditioned media was collected from cells, concentrated using
AmiconUltra-4 columns and 1/20 of original volume loaded on the Zymogram Gelatin Gels (Life
Technologies) and developed according to the manufacturer’s recommendations.
MMP14-specific fluorogenic substrate degradation assay. 2x104 cells were plated on 96w
plate, for 16 hours, followed by 1 hour in L15 media (Life Technologies). MMP14-specific
IOXRURJHQLFVXEVWUDWH 0LOOLSRUH ZDVLQWURGXFHGLQILQDOFRQFHQWUDWLRQȝ0)OXRUHVFHQFHZDV
measured at 328/400mn every 5 minutes for 12 hours, using Synergy H4 Plate Reader
(BioTek). Averaged background signal was subtracted, and data plotted curves described by
equation for one site binding kinetics and fitted to each data set with the R2 of 0.8 The curves
were significantly different between control and NEDD9 deficient cells according to the Extra
sum ofsquares F test, p<0.0001.
ECM coated Boyden chamber invasion assays. Invasion assays were performed using BD
FluoroBlok™ insets coated with matrigel (BD Biosciences). Cells were added to the top
chamber in serum free media, 10%FBS supplemented MEM was added to the bottom chamber,
and incubated for 8h. Once cells migrated through the matrix, they were labeled with Calcein
AM (Life Technologies) and detected by fluorescence plate reader (Genios) at 485/530nm
excitation/emission.
Cell viability Trypan Blue exclusion assay. MDA-MB-231-shCon, -shNEDD9 cells were
cultured in suspension using Ultra-Low attachment plates (Fisher Scientific) for 36 hours; 0.1
mL of a 0.4% solution of trypan blue in PBS was added to 1x106/mL of cells. The total number
of cells and the number of blue staining cells were calculated by Countess automated cell
counter (Life Technologies). Number of viable cells × 104 × 1.1 = cells/mL culture.
Fluorescence Activated Cell Sorting (FACS). 1x106 cells, with or without permeabilization by
0.5% Tween20 (Sigma), were stained for MMP14 (Novus International). Secondary
fluorescence conjugated antibodies (BD Biosciences) were used at a concentration 0.5ug/1
x106 cells. Cells were pre-blocked with 5mg/ml of Human IgG (Sigma). As a control, nonspecific primary antibody, either Rabbit or mouse IgG were used (Sigma).
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Western blotting (WB). Western blotting was done using standard procedures (26, 30).
Primary antibodies included mouse anti-NEDD9 mAb (2G9) (29), anti-phTyr, (Cell Signaling
Technology Inc.), anti-p130Cas, -MMP2, -MMP9, -GAPDH, -RFP (ThermoFisher), anticortactin,
-MMP14 (Novus), anti-ȕ-actin, -Į-tubulin, (Sigma) antibodies. Secondary HPRconjugated
antibodies and chemiluminescence-based detection and quantification methods were previously
described (30).Recombinant
TIMP2 titration assay. Recombinant human TIMP2 was purchased from Life Technologies,
diluted in cell culture medium and added to the cells in 0-100nM final concentration for 6-12h.
After indicated times cells number of invaded cells was calculated as described in Boyden
chamber invasion assay.
Immunofluorescence (IF). IF was performed as previously described (30). Primary antibodies
included: rabbit anti-phTyr, -Arp3, -N-WASP (Cell Signaling Technology), anti-cortactin, MMP14 (Novus), anti-cortactin (4F11). The secondary antibodies included: Alexa Fluor 405,
488, 555 donkey anti-rabbit, and Alexa Fluor 647 goat anti-mouse and Rhodamine-540 or
PacificBlue-405-conjugated phalloidin (Life Technologies). Images were captured by confocal
microscope LSM 510 (Carl Zeiss). To analyze IF data, volumes of positively stained structures
were evaluated per cell. Quantifications were performed on z stack projections, and collected
using standard acquisition parameters with ImageJ (NIH) and LSM Image analysis software
(Carl Zeiss).
Tissue Microarrays (TMA) and Immunohistochemistry (IHC). The high density BCa tissue
microarrays were purchased from US Biomax Inc., and content is outlined in Supplementary
Table 1. All procedures were approved by the Institutional Biohazard Committee of West
Virginia University. TMA sections were deparaffinized, endogenous peroxidase activity was
quenched with 3% hydrogen peroxide, and slides were incubated with anti-NEDD9 antibodies
(1:100 dilution) overnight at 4C; followed by staining with secondary peroxidase-labeled
antibodies and developed with DAB (DAKO). Positive and negative controls were included with
each run. Staining was done in duplicate. The IHC analysis and scoring protocol is available in
Supplementary materials.
Lung metastasis analysis. Lungs were collected and fixed in 4%PFA for 24-48h embedded in
paraffin by WVU Tissue Bank as previously described (30). Serial 6-ȝPWKLQNVHFWLRQVZHUH
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FXWDWHDFKȝPVWHSVWKURXJKWKHZKROHRUJDQ6HFWLRQVZHUHVXEMHFWHGWRKHPDWR[\OLQDQG
eosin (H&E) staining. Metastatic lesions were visually identified and images were acquired
using Zeiss Axioplan microscope with x4 and x10 NA1.6 objective, followed by higher x100
magnification evaluation of whole section. Multiple sections from each lung/mouse were
analyzed in each cohort. Quantification of the metastases was done by WVU pathologist (Dr.
Livengood) using serial sections of lungs and H&E staining. Results are plotted as mean
number of metastases per mm2 +/ S.E.M, 3 independent experiments, n=6-10 per treatment
group.
Animal Studies. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ/(NSG) immunodeficient mice were
purchased from the Jackson Laboratory. Animals were housed in the WVU Animal Facility
under pathogen-free conditions and approved by the Institutional Animal Care and Use
Committee protocol. Primary tumors and lungs were collected, processed for histopathology,
and analyzed by the WVU Tissue Bank Core Facility.
Animal Bioluminescence Imaging (BLI) mammary fat pad injections. For orthotopic
injections luciferase-expressing MDA-MB-231LN and BT-549 cells expressing Control (Con) or
NEDD9 (N1, N4) targeting shRNAs were grown, trypsinized, and resuspended in PBS (1×107
cells/ml), and 0.1 ml was injected into the 4th inguinal mammary gland of 6-8 weeks old NSG
female mice. Tumor cells were injected in 6 mice and the experiments were repeated at least 3
times resulting in a total of 18 mice per cell line/per shRNA. Mice were imaged weekly for
quantitative evaluation of tumor growth and dissemination for up to 6 weeks. For
doxycyclineinducible shRNAs Dox diet (BioServ, S3888, 200mg/kg doxycycline) was introduced
to start the shRNA expression when primary tumors in all experimental cohorts had reached
similar size of 200mm3 (2-3 weeks post injection). shRNA expression was monitors by the
increase in RFP fluorescence. 150 mg/kg D-Luciferin (Perkin Elmer) was injected into the
peritoneum. Images were obtained using the IVIS® Lumina-II Imaging System and Living
Image-4.0 software (Perkin Elmer).
Isolation and characterization of circulating tumor cells (CTC) from Peripheral Blood.
Blood was collected from DQLPDOVZHHNO\YLDVXEPDQGLEXODUEOHHGLQJ$ERXWȝORIEORRGZDV
collected into centrifuge tubes containing anticoagulants (EDTA, heparin). Peripheral blood was
depleted for erythrocytes using RBC Lysis buffer (eBiosciences) according to manufacturer’s
guidelines. The presence of nucleated tumor cells was detected by co-staining with DAPI and
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quantified by direct fluorescence, of RFP-induced by Doxycycline only in tumor cells (red) was
measured under fluorescence microscope.
Statistical Analysis. Statistical comparisons were made using two-tailed Student’s t test. When
more than two groups were analyzed, one-way analysis of variance (ANOVA) was used. P
was considered to be significant. Experimental values were reported as the means with +/S.E.M. All calculations were made using the GraphPad InStat software. Random forests
analysis provides an aggressive machine learning approach for classifying data into groups
using ensembles of regression trees. Using this approach, we quantified the influence of
NEDD9 IHC intensity staining in prediction of disease stage by the construction of the
regression trees using a variable importance score averaged over all the trees.
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Results
Increase in NEDD9 protein correlates with an invasive state in BCa. To assess the role of
NEDD9 in cancer progression, we screened two independent TMAs using immunohistochemical
staining (IHC) comprised of 200 BCa cases. Figure 1A shows representative images of NEDD9
staining in normal, DCIS (ductal carcinoma in situ), IDC (invasive ductal carcinoma), and MIDCLN (metastatic invasive ductal carcinoma, lymph node). Statistical analysis of anti- NEDD9
staining intensity performed either by automated image capture system (Fig.1B) or visual
evaluation by pathologist (Suppl.Fig.1A) suggests that NEDD9 levels positively correlate with
disease progression. The lowest intensity was found in normal tissue, followed by a 10 fold
increase in DCIS and a 30 fold increase in IDC, whereas only a 10 fold increase in expression
was observed in MIDC-LN (Fig.1B). Random forest statistical analysis of NEDD9 staining, which
achieved an out-of-bag error rate of 0.49, indicates that by using NEDD9 protein levels, one can
double the predictive power over chance of classifying tumor. The independent prognostic value
of NEDD9 expression had 70% probability of identifying cases of IDC (Fig.1C).
NEDD9 expression in BCa cells correlates with the capability to degrade ECM. We used a
panel of characterized human BCa cell lines to determine if NEDD9 expression profiles
identified in BCa patient samples correlate with invasion potential of cells,. We found that
NEDD9 protein levels varied across the different cell lines in contrast to the p130Cas/BCAR1
protein (Fig.1D-E). Several BCa cell lines including MDA-MB-231, ZR-75-1, and BT-549 have 5
to 8 fold more NEDD9 when compared to the non-transformed MCF10A line. The high NEDD9
expression levels correlate with the invasive capabilities of these cells (31-32). We confirmed
these findings using FITC-gelatin degradation assays. Representative images and quantification
of degradation by MCF7, BT-549 and ZR-75-1 shown in Figure 1F-G and Suppl.Fig.1B. In
contrast to the highly invasive MDA-MB-231 and BT-549, the AU-565 and MCF7 BCa cells were
not proficient in gelatin degradation. We and others previously noticed that these cells
expressed low levels of cortactin (Fig.1D), MMP14, and MMP2 (33) which are required for
invasion (16). This indicates that NEDD9 is required to support ECM degradation, although
other components of the invasion machinery are also required for these processes.
NEDD9 localizes to and promotes invadopodia maturation. To define the requirement of
NEDD9 in formation and function of invadopodia, we infected MDA-MB-231, BT-549, and ZR75-1 cells with two different shRNAs targeting NEDD9, which did not effect the expression of
p130Cas (Fig.2A). Cells were plated on FITC-gelatin coated coverslips and co-stained with
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invadopodia markers F-actin and cortactin to visualize the area of gelatin degradation and
pseudopods (Fig.2B-C). Depletion of NEDD9 led to a two- threefold reduction in the number of
cells degrading matrix, while viability of cells was not affected (Fig.2D). Interestingly, NEDD9
depleted cells had a similar number of F-actin/cortactin rich puncta (Fig.2E) which are found
during the initial stages of invadopodia formation (16) but show an absence of degradation
beneath the puncta (Fig.2C). p130Cas, which is highly expressed in BCa cells (Fig2A), was not
able to compensate for the decrease in NEDD9 under current experimental settings suggesting
a critical role of NEDD9 in invadopodia based invasion in BCa. The localization of other major
components of invadopodia, such as: Arp3 and N-WASP, were not affected by depletion of
NEDD9 (Suppl.Fig.1C). To determine if NEDD9 localized to invadopodia in BCa cells, we costained cells with anti- NEDD9 antibodies (29) and invadopodia markers (16). We found that
NEDD9 was consistently co-localized with cortactin, actin, and phTyrosine (Fig.2F-G) in all cells
with invadopodia.
NEDD9 depletion in BCa cells leads to decrease in 3D invasion. To assess the impact of
NEDD9 depletion on ECM degradation under more physiological conditions we used matrigelDQcollagen I/IV invasion assay to trace invasion and pericellular ECM degradation in 3D matrix.
BCa cells treated with shRNAs against NEDD9 were deficient in matrix degradation when
embedded in 3D matrix (Fig.3A-C). The levels of FITC-fluorescence as a result of proteolytical
cleavage of DQcollagen I/IV were calculated (Fig.3B) in shRNA expressing RFPpositive cells.
The results were also evaluated in BT-549 and ZR-75-1 cell lines (Suppl.Fig.2AB). shNEDD9
cells demonstrated severe deficiency in collagen I/IV degradation indicated by a six fold
decrease in fluorescence. We observed that the area of degradation in control cells had either a
pericellular or dotted pattern (insert, Fig.3A).
NEDD9 knockdown decreases MMPs activity, but does not affect MMPs expression or
secretion. MMPs are the key enzymes responsible for matrix degradation. To determine the
potential impact of NEDD9 on the function of MMPs, we analyzed protein levels of MMPs in
shNEDD9 and control cells using a comprehensive MMP antibody array. Serum-free medium
(SFM) conditioned by control and shNEDD9 cells was collected to measure the levels of
secreted MMPs. The whole cell lysates (WCL) were used to define the total protein level of
various expressed MMPs. No significant differences in the total amount of produced or secreted
MMP and tissue specific inhibitor of MMP- TIMPs, were detected (Fig.4A-B), except MMP13
which was slightly elevated in shNEDD9 cells. Nevertheless, analysis of SFM conditioned by
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shNEDD9, but not control, using EnzChek Gelatinase/Collagenase assay shows a severe
deficiency in the activity of secreted collagenases (Fig.4C). Next, we tested the activity of
secreted MMPs by gel zymography. The activity of MMPs, particularly MMP2 and MMP9, was
reduced by 60-80% upon NEDD9 depletion (Fig.4D-E), indicated by the decrease in the amount
of active 68kDa form of MMP2 (Fig.4D, quantification of 68kDa form Fig.4E) and 92-86kDa
forms of MMP9 (Fig.4E). We then tested the activity of MMP14 using a MMP14-specific
fluorogenic substrate and show that NEDD9 depletion results in a significant decrease in
MMP14 activity (Fig.4F).
NEDD9 depletion leads to inactivation of MMP14 by TIMP2. Membrane bound MMP14 is
one of the key molecules involved in activation of soluble MMPs and pericellular degradation
(34). Total MMP14 protein level (Fig.5A) and localization patterns (Suppl.Fig.2C) were not
impacted by NEDD9 depletion. Interestingly, cell surface levels of MMP14 and TIMP2 proteins
assessed by FACS (Fig.5B-C) and IF (Fig.5D-E) had increased up to 40% upon NEDD9
depletion. Note, that according to the MMP array analysis performed earlier depletion of NEDD9
did not affect total expression or secretion of TIMP2 (Fig.4A-B). TIMP2 is a well-known regulator
of MMP14 and MMP2 activity. An increased amount of TIMP2-bound MMP14 is indicative of its
decreased activity (35-36). Depletion of MMP14 (Fig.6A) and TIMP2 in BCa cells (Fig.6B), using
specific siRNAs, resulted in a similar to shNEDD9 invasion deficiency (Fig.6C) suggesting that
MMP14 and TIMP2 are potentially the downstream targets affected by NEDD9. Moreover,
addition of increasing amounts of recombinant TIMP2 to the medium of control cells leads to a
similar inhibition of invasion at the higher concentrations of TIMP2 (Fig.6D). Importantly, reexpression of NEDD9 (Fig.6E) restored the amount of surface-bound MMP14 (Fig.6F) and
invasion proficiency of shNEDD9 cells (Fig.6G).
NEDD9 depletion inhibits invasion and intravasation of tumor cells from primary site and
growth of metastasis in xenograft models. To determine the requirements of NEDD9 for
invasion and metastasis in vivo, we utilized human tumor xenografts combined with
bioluminescence imaging (BLI) (27, 30). MDA-MB-231-shCon and shNEDD9 (N1, N4) cells
were injected into the mammary fat pad and allowed to develop primary tumors without
induction of shRNA. When tumor volume reached 150-200mm3 (Fig.7A-shRNA-Day0), animals
were placed on doxycycline-containing food. shRNA expression was monitored by RFP
fluorescence, along with BLI (Fig.7A-shRNA-Day14) and western blotting (Fig.7B). Animals
were euthanized at shRNA Day0 or Day14 which corresponded to 3, and 5 weeks post injection
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of tumor cells to assess for the number of CTCs in the peripheral blood, number and size of
metastases in the lungs and gross pathology of primary tumor. At the shRNA Day0, all animals
had similar primary tumor size and volume based on caliper measurements and BLI
(Fig.7CshRNA-Day0). Analysis of peripheral blood samples for CTCs reveals similar number in
all three cohorts of animals (shCon/shN1/shN4) (Fig.7D-shRNA-Day0), as well as similar
number of metastases seeded in the lungs (Fig.7E-shRNA-Day0). NEDD9 depletion during the
following 14 days in established primary tumors and metastases led to a drastic decrease in the
number of CTCs (Fig.7D-shRNA-Day14) and number of metastases in lungs (Fig.7E-F-shRNADay14). The primary tumors had continued to grow during the shRNA induction based on BLI
data (Fig.7C-shRNA-Day0/Day14); thus, the decrease in the number of CTCs could be either
due to a decrease in the ability of tumor cells to invade the surrounding matrix and intravasate in
blood stream or due to decrease in overall survival. We have established that NEDD9 depletion
did not affect the survival of MDA-MB-231 cells (Fig.7G). Similar results were obtained with
another metastatic BCa cell line BT-549 supporting the general phenomenon of NEDD9 function
in invasion and metastasis (Suppl.Fig.3A-D). Collectively, our findings suggest that the
application of shRNAs against NEDD9 to already established tumors could drastically reduce
the number of tumor cells released into circulation due to an invasion deficiency, thereby,
eliminating further seeding and decrease the total number of metastasis.
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Discussion
While recent studies have established NEDD9 as an essential factor for invasion (2-4)
and metastasis (1, 37) the precise mechanism of how NEDD9 functions and its contribution to
various stages of metastasis have been poorly defined. In our current study we show that
NEDD9 is upregulated in breast tumors, and specifically increases in IDC, giving NEDD9 the
potential to serve as a strong diagnostic marker for invasive tumors.
Interestingly, NEDD9 is decreased in metastatic samples suggesting that high level of
NEDD9 is required during the invasion from the primary site, most probably to enable proteasedependent degradation of the basal membrane and EMT re-programming. While still increased
compared to normal tissue, lesser amounts of NEDD9 are sufficient during growth at distant
metastatic sites. Alternatively, upon arrival at distant sites, a decrease in NEDD9 expression
might be beneficial in order to undergo mesenchymal to epithelial transition to establish the
colony (8). These data is in accordance with the previously published studies showing that
established metastasis in lungs had less NEDD9 when compared to primary tumor (6-7, 21-22).
It is possible that decrease in NEDD9 might be beneficial for migration through filamentous
collagen rich matrices; while in the basal membrane like matrix, the presence of NEDD9 was an
absolute requirement for efficient invasion.
Decreases in NEDD9 expression, induced by constitutive or inducible shRNAs against
NEDD9, result in a dramatic decrease in matrix degradation and invasion of BCa cells in 2D, 3D
environments, and limits number of CTCs and metastases, thus establishing NEDD9 as an
important factor for invasion and metastasis in BCa. In a search for a molecular mechanisms
underlying NEDD9 dependent invasion, we found that depletion of NEDD9 does not affect
formation of nascent invadopodia, characterized by aggregation of F-actin, cortactin, and
MMP14 (17), but prevents further maturation of invadopodia into proteolytically active structures
(16). These findings are in agreement with previous report in SCC-9 cells where NEDD9
expression was required for matrix degradation, but disagree with regard of NEDD9 requirement
for invadopodia formation (23). The differences might be associated with artificial exogenous
overexpression of NEDD9 in SCC9 cells. The source of differences could also reside in tissue
specific behavior of breast versus head and neck cells. It is also needs to be noted that another
NEDD9 family member protein p130Cas was previously identified in invadopodia (24). In the
cell lines used in our study depletion of NEDD9 did not affect the formation of invadopodia,
indicating the different roles of these adaptor proteins in invasion.
The maturation of invadopodia in BCa cells and the capacity of tumor cells to invade
surrounding tissue are directly linked to accumulation and activation of MMP14 and soluble
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MMPs (10, 34). We found that depletion of NEDD9 leads to a 60-80% decrease in activity of
secreted MMP2 and MMP9 and pericellular proteolysis. Activity of MMP14 is tightly regulated by
TIMP2 which plays dual roles as both inhibitor and activator of MMP14, depending upon
concentration (35-36). While there is no difference in produced or secreted protein levels of
MMPs and TIMPs in shNEDD9 and shCon cells, we observed that the concentration of cell
surface bound TIMP2 and MMP14 is up to 50% higher in shNEDD9 cells, suggesting that the
decrease in activity of MMP14 and other MMPs is potentially due to an increased amount of
TIMP2 associated with MMP14 on the cell surface. Interestingly, depletion of MMP14 or TIMP2
results in a similar decrease in MMP2 activity and invasion deficiency recapitulating the
shNEDD9 phenotype. TIMP2 is a potent inhibitor of most soluble MMPs (39), thus TIMP2
depletion could also relieve the inhibition of other soluble MMPs produced by cells.
Nevertheless, our findings indicate that depletion of TIMP2 alone is not sufficient to restore the
activity of soluble MMPs most likely due to the presence of other TIMPs such as TIMP1, 3 and 4
(39-40). Re-expression of NEDD9 restores the MMPs activity and invasion proficiency of
shNEDD9 cells.
Binding of TIMP2 results in increased endocytosis of MMP14 (10, 38) followed by
dissociation of MMP14/TIMP2 complexes within the endocytic vesicles and regenerate an active
protease (34). Accumulation of MMP14/TIMP2 complexes on the cell surface is indicative of
endocytotic deficiency in NEDD9 depleted cells. Interestingly, MMP14 can be phosphorylated
by Src kinase and this phosphorylation is required for invasion and endocytosis of MMP14 (19),
thus directly linking the NEDD9 dependent decrease in Src and FAK activity (4, 21) with
inactivation of MMP14. Further work is required to uncover the intricate link between NEDD9
and MMP14 trafficking.
The decrease in number of metastases and CTCs upon NEDD9 depletion in cancer cells
could advocate for development of shRNA based NEDD9-targeted therapy against BCa
invasion. Importantly, even established, late stage, cancers with seeded metastases based on
our in vivo inducible xenograft studies might still benefit from shNEDD9 treatment and prevent
further spreading of disease. Collectively, our findings establish a critical role for NEDD9 as a
regulator of invasion in BCa through modulation of MMP14 activity, thus delineating a new
signaling pathway for targeting NEDD9 dependent invasion.
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Figure legends
Figure 1. NEDD9 is overexpressed in invasive breast ductal carcinomas and BCa cell
lines. (A). Representative images of IHC staining with anti-NEDD9 antibodies in normal breast,
DCIS, IDC MIDC-LN. (B). Statistical analysis of NEDD9 expression based on intensity of
staining in (A), mean values +/-S.E.M, one-way ANOVA*, p<0.001 (Normal/IDC, Normal/MIDC
LN, Normal/DCIS), p<0.05 (DCIS/IDC, IDC/MIDC-LN), ns-non significant (DCIS/MIDC-LN) (C).
The data (B) were analyzed by Random forest statistical software to assess the predictive value
of NEDD9 expression. (D). Western Blot analysis (WB) of NEDD9, p130Cas, cortactin and
tubulin in the indicated cell lines. (E). Quantification of NEDD9 and p130Cas as in (D),
normalized to MCF10A, * p<0.001. (F). Immunofluorescent (IF) staining of MCF7 and BT-549
cells with Rhodamine-Phalloidin (red) and cortactin (green), FITC-gelatin (white). (G).
Quantification of matrix degradation, 100 cells/cell line n=3, % of cells degrading matrix, +/S.E.M, * p<0.0001 one-way ANOVA.
Figure 2. NEDD9 localizes to and promotes invadopodia maturation. (A). Top: WB of
NEDD9, p130Cas, actin in MDA-MB-231-shNEDD9 or -shCon cells, Bottom: quantification of
NEDD9 and p130Cas expression normalized to shCon; one-way ANOVA, p<0.001. (B). IF
staining of MDA-MB-231-shCon and -shNEDD9 cells with anti-cortactin (green), -actin (red)
antibodies and FITC-gelatin (blue), scale bar 10

Ů įġŊůŴ Ŧ ųŵŴ ġŢ ųŦ ġ

main panel. (C). Enlarged XYZ projections of IF as in (B). (D). Quantification of number of cells
degrading matrix and F-actin/cortactin positive foci (E) in MDA-MB-231-shCon, - shNEDD9 (N1,
N4) cells. Student’s t-test for (D): *p<0.001(shCon/shN1, shCon/shN4), ns - shN1/N4; and ns
(E) +/-S.E.M. (F). IF of MDA-MB-231 cells with cortactin (blue), actin (red) and NEDD9 (green),
and FITC-gelatin (white). (G). IF staining with anti-phTyr (blue), actin (red) and NEDD9 (green)
antibodies, and FITC-gelatin (white). Scale bar -

ŮįġŊůŴ Ŧ ųŵŴ ġŢ ųŦenlarged
ġ
areas indicated in

the main panel.
Figure 3. NEDD9 depletion ablates matrix degradation and invasion in 3D matrices. (A).
Representative images of 3D projections live cell imaging of MDA-MB-231-shCon, -shNEDD9
cells embedded in the DQ-CollagenI/IV/matrigel matrix, shRNA (red), DNA (blue) at indicated
time points; xyz projections (z), scale bar -50

Ů įġŊůŴ Ŧ ŵŴ ġŢ ųŦ ġŦ ů

rectangle. (B). Quantification of FITC-fluorescence intensity as in (A), % of area degraded per
cell, +/-S.E.M, *p<0.0001 one-way ANOVA. (C). WB of cells in (A-B) with anti-NEDD9 and actin
antibodies. +Dox indicates the lines used in A-B.
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Figure 4. NEDD9 depletion decreases MMPs activity, but does not affect MMPs
expression or secretion. (A). WB of total MMPs expressed (WCL) and secreted (SFM) by
indicated cells, 48h post shRNA expression. Schematic outline the MMP microarray. (B).
Quantification of MMPs and TIMPs expression, n=3, one-way ANOVA for all pairs p is non
significant; p<0.05 for MMP13 (shCon/shN4). (C). Quantification of gellatinase/collagenese
activity in SFM conditioned by cells using EnzChek Gellatinase/Collagenese assay. Clostridium
Collagenase, 0.1U/ml, is positive control, p<0.05 (shCon/shN1 or /N4), linear regression
analysis. (D). Representative image of -gel zymography, SFM conditioned by MDA-MB-231
shCon, - shNEDD9 cells, WB of MMP2 and MMP9. (E). Quantification MMP2 and MMP9 activity
as in (D) normalized to total level of MMP2 and MMP9, +/-S.E.M; MMP9: p=0.007 (*) shCon/N1,
or /N4 and ns - shN1/N4, one-way ANOVA. MMP2: p=0.00031, shCon/N1, /N4, ns -shN1/N4,
one-way ANOVA. (F). MMP14-specific fluorogenic substrate assay, at 328/400mn. Data plotted
as curves described by equation for one site binding kinetics, fitted to each data set with the R2
of 0.8, Extra sum-of-squares F test, p<0.0001.
Figure 5. NEDD9 depletion leads to increase in amount of surface-bound TIMP2 and
MMP14: (A). WB of WCL with anti-NEDD9, -MMP14, -GAPDH antibodies. (B). FACS of
MMP14: surface (non-permeabilized) and total (permeabilized) normalized to shCon; one-way
ANOVA *p<0.005 (shCon/N1 or /N4) -surface cells, ns, -total. (C). FACS of TIMP2-surface,
normalized to shCon; t-test *p=0.039 (shCon/N1), *p=0.0029 (shCon/N4). (D). Representative
images of IF, MDA-MB-231-shCon, -shNEDD9 cells with anti-TIMP2 antibody (red), DNA (blue).
Scale bar, 20

Ů įġŊůŴ
Ŧ ųŵŴ ġŢ ųŦ ġŹĲııġŮ Ţ ŨůŪŧŪŦ ťġŢ ųŦ
(E).
Quantification

of TIMP2 fluorescence intensity at the membrane as in (D) normalized to shCon; t-test *p<0.001
(shCon/shN1 or /N4), ns - shN1/shN4.
Figure 6. Inhibition or depletion of MMP14 or TIMP2 recapitulates invasion deficiency of
shNEDD9 cells. (A-B). WB of WCL of MDA-MB-231-shCon, -shNEDD9 cells treated with
siCon, siMMP14 or siTIMP2, using anti- NEDD9, -TIMP2 and -a-tubulin antibodies. (C). Boyden
Chamber invasion assay, cells as in (AB); plotted as relative fluorescence units (RFU), one-way
ANOVA *p<0.0001 (shCon/siCon, shN1/siCon, or shN4/siCon), ns -shN1/N4-siCon and
shCon/siMMP14 or shCon/siTIMP2; p<0.005 shCon/siCon, shCon/siMMP14 or shCon/siTIMP2;
(D). Boyden Chamber invasion assay of MDA-MB-231-shCon cells with increased amount of
TIMP2. MDA-MB-231-shN4 cells used as a reference control. Results plotted as RFU, n=3.
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One-way ANOVA *p<0.0001 shCon-0nM/shCon-10nM or more, ns: shN4/shCon-10nM. (E). WB
of NEDD9 rescue in MDAMB- 231-shCon, -shNEDD9 cells with empty vector or cDNA-NEDD9
construct, using anti- NEDD9, GAPDH antibodies. (F). FACS of MMP14 surface staining as in
(E); one-way ANOVA *p<0.0001 empty vector-shCon/shN1 or /N4; ns cDNANEDD9
shCon/shN1 or /N4). (G). Boyden-Chamber assay, cells as in (E-F). Data plotted as RFU, one
way ANOVA *p<0.0001 (shCon-empty/shCon-NEDD9, shN1-empty/shN1-NEDD9, shN4
empty/shN4- NEDD9); p<0.005 (shCon-empty/shN1-empty or -shN4-empty); ns (shCon
NEDD9/shN1- NEDD9 or /shN4-NEDD9).
Figure 7. NEDD9 depletion inhibits metastasis in xenograft models. (A). Representative
images of bioluminescence and RFP fluorescence of mice orthotopically injected with MDAMB231LN-shCon or –shNEDD9 cells. shRNA-Day0-3 weeks post injection, regular chow; shRNA
Day14-2 weeks doxycycline chow; 6 mice/shRNA/3 independent experiments. (B). WB of
primary tumor tissue at (shRNA-Day0, -Day14) with anti-NEDD9, -RFP and –actin antibodies.
(C). Quantification of tumor growth based on bioluminescence in 3 independent experiments,
n=6/group, mean photon flux, +/-S.E.M, one-way ANOVA, p is ns for shRNADay0 (shCon/shN1
or /N4), shRNA-Day14 (shCon/shN1, shN1/shN4); *p=0.032 for shRNADay14- shCon/shN4.
(D). Quantification of RFP/luc2/DNA positive tumor cells in peripheral blood of shCon and
shNEDD9 mice at indicated times, n=6/group/3 independent experiments; plotted as mean
number of cells per 200

-S.E.M,
ŭġŰŧġţŭŰŰťĭġĬİ
two-way ANOVA, ns (shRNADay0: shCon/shN1

or /N4); p<0.001 (shRNA-Day14: shCon/shN1 or /N4). (E). Quantification of metastases in lungs
of orthotopically injected animals at indicated times by pathologist using serial sections of lungs
and H&E staining, plotted as mean number of metastases per mm2 +/- S.E.M, n=6/group/3
independent experiments; two-way ANOVA p -ns (shRNA-Day0: shCon/shN1 or /N4); p<0.001
(shRNA-Day14: shCon/shN1 or /N4). (F). Representative images of H&E staining as in (E).
Scale bar-500

-insert.
ŮĭġŮ Ţ(G).
ŪůġűŢQuantification
ůŦ ŭĭġĶı Ů ġ of number of trypan blue

negative vs. positive shCon or shNEDD9 cells, 72 in suspension. One- way ANOVA, p=0.0946.
Supplementary Figure 1. (A). Statistical analysis of NEDD9 expression based on intensity and
number of positively stained cells in Fig.1(A) visually determined by two pathologists according
to the scoring procedure described in Material and Methods section. (B). Immunofluorescent
(IF) staining of ZR-75-1 cells with Rhodamine-Phalloidin (red) and cortactin (green), FITCgelatin (pseudo colored white). (C). Immuofluorescent analysis of structural components of
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invadopodia: Arp3 (green), N-WASP (green), cortactin (red), DNA (blue), FITC-gelatin (white) in
MDA231- MB-231-shCon, -shNEDD9 (N4) cells.
Supplementary Figure 2. (A). Representative images of live microscopy of BT549-shCon, shNEDD9 (N4) cells embedded in DQ-Collagen IV 48h post plating. DNA (blue), shRNA
expressing cells (RFP, red) and degradation of DQ-Collagen (green). (B). Quantification of
DQCollagen IV degradation as shown in (A). Statistical analysis by one-way ANOVA based on 3
independent experiments in 100-200 cells in each group. *p<0.005 (shCon/shN1 or N4), ns
(shN1/N4). (C). IF analysis of MDA-MB-231-shCon, -shNEDD9 cells with anti-cortactin (blue),
anti-F-DFWLQ UHG DQG003 JUHHQ DQWLERGLHV6FDOHEDULVȝP:KLWHDUURZVLQGLFDWH
membrane area with increase in MMP14.
Supplementary Figure 3. (A). Representative images of bioluminescence (BLI) of mice
orthotopically injected with BT-549 cells expressing doxycycline inducible shCon or shNEDD9
(shN1) RNAs. shRNA-Day0 represents 2 weeks post injection, before addition of doxycycline
chow; shRNA-Day14 is 2 weeks post addition of doxycycline-containing diet. 6 mice/each
shRNA (12 mice total). (B). WB (right panel) analysis of primary tumor tissue dissected at
shRNA-Day14 with anti-NEDD9, and -GAPDH antibodies. Quantification of sRNA depletion 2
(left panel) from tumors from 3 mice/per shRNA, t-test *p=0.0019. (C). Quantification of tumor
growth based on BLI (shRNA-Day0, -Day14) in 3 independent experiments, n=6/group, mean
photon flux, +/-S.E.M, two-way ANOVA, p values are non-significant (ns) for shRNA-Day0
(shCon/shN1); *p=0.0007 for shRNA-Day14 (shCon/shN1). (D). Quantification of RFP/luc2/DNA
positive tumor cells in peripheral blood of shCon and shNEDD9 (N1) mice at indicated time
points, n=6/group. Results are plotted as number of cells per 20ȝORIEORRG- S.E.M, two-way
ANOVA, ns (shRNA-Day0: shCon/shN1); p<0.001 (shRNA-Day14: shCon/shN1).
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Study 3: Generation of a Mammary Specific Nedd9 Knock-in Mouse
Model
Ryan J. Ice and Elena N. Pugacheva
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Abstract
NEDD9 protein levels are often increased in many types of cancers and are an
established indicator of poor prognosis. Breast cancer patient samples containing high levels of
NEDD9 correlate strongly with a more invasive and metastatic phenotype. Additionally, in breast
cancer cell lines, NEDD9 plays a critical role in the formation of active invadopodia and
increased migration. In order to investigate the impact of NEDD9 overexpression in vivo, we
generated a transgenic mouse model with an extra copy of inducible human NEDD9 cDNA
inserted into the ROSA26 locus on chromosome 6 , which when crossed with any tissue specific
Cre recombinase expressing mouse strain, will result in overexpression of NEDD9. To assess
the specific role of NEDD9 overexpression in mammary tumorigenesis and mammary gland
development, we crossed the founder line with a mouse strain expressing Cre recombinase
under the control of the mouse mammary tumor virus promoter, MMTV-Cre. The resulting line
overexpresses NEDD9 protein specifically in the mammary gland epithelial tissue. The MMTVCre-NEDD9+/+ mice were further crossed with the MMTV-Her2 line to mimic oncogene-driven
tumorigenesis often seen in Her2 overexpressing patients in human breast cancer. The control
MMTV-Cre,

MMTV-Cre/NEDD9+/+

and

experimental

MMTV-Her2

and

MMTV-

Cre/NEDD9+/+/Her2 lines were successfully produced and further studies will be needed to
examine tumor initiation and progression. The characterization of mammary gland development
in founder MMTV-Cre- NEDD9 line was completed and showed a significant increase in the
branch to bud ratio indicating a possible increase in invasion potential during mammary gland
development. Taken together the generation of a transgenic mammary gland specific NEDD9
overexpressing model will aid in uncovering the impact of NEDD9 on tumor initiation and
progression.
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Introduction
Invasive breast cancer remains a difficult to treat disease effecting one in eight women
during their lifetime, often with poor prognosis when metastases are present at the time of
diagnosis (Siegel 2012, Rugo 2008). Although mutations in tumor suppressor genes such as
p53 are oncogenic, it is common that increases in signaling not due to mutation are found in
pro-metastatic and pro-survival signaling proteins such as: Src, FAK, and Akt (Dimri 2007,
Lahlou 2007, Maroulakou 2007). NEDD9, a scaffolding protein commonly overexpressed in
various tumor types including breast, is known to enhance the activity of such pathways leading
to increased invasion, migration, and survival resulting in poor prognosis (Izumchenko 2009).
In order to dissect the role of NEDD9 protein in mammary tumorigenesis in vivo it is
imperative to define first if overexpression of NEDD9 affects normal mammary epithelium
function. Additionally, the role of NEDD9 in mammary gland development is an area that has not
yet been explored. Since NEDD9 has been shown to increase the activity of MMPs and
degradation in human tumors, and mammary gland bud formation has been shown to be an
MMP dependent process it would stand to reason that NEDD9 may play a role in mammary
gland development (McLaughlin 2013, Fata 2004).
We adopted the strategy of overexpressing human NEDD9 in the mammary gland alone
instead of the entire mouse since NEDD9 has been reported the play a role in Alzheimer
disease and necessary cilia functions in the gonads important for fertility (Zhang 2006). To date,
there are no known tumorigenic mutations of NEDD9, however NEDD9 is commonly
overexpressed and is known to be involved in tumorigenesis. The importance of NEDD9 in
mammary tumorigenesis has been illustrated previously by knocking out Nedd9, in the context
of an oncogene driven spontaneous tumor model system (Izumchenko 2009). Nedd9 knockout
in the context of MMTV-PyVmT and MMTV-neu mouse mammary tumor models showed a
decrease in the incidence, increased latency , reduced tumor size and reduced number of
metastasis when compared to original MMTV-PyVmT mice.
When crossed with MMTV-Her2, Nedd9 knock out animals show a difference of 56% in
the number of mice that form tumors within one year of age. It should be noted however that the
Cas family member, p130Cas does have the ability in many instances to compensate for the
loss of Nedd9. We believe our novel model system more accurately recapitulates patient
tumors, since patients present with increased levels of NEDD9 protein, and that p130Cas
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compensation is not a factor in overexpression we feel our model to be more clinically relevant
and possess the ability to test NEDD9 targeted therapies.
The purpose of this study is to evaluate the role of NEDD9 overexpression in the
development of mammary gland tumors in the physiologically relevant context. Wild type human
NEDD9 will be specifically expressed only in the mammary gland epithelia via the MMTV
promoter. Upon confirmation of specific and significant expression of NEDD9 (recapitulating the
expression of NEDD9 in human tumors) in mammary epithelium this strain will be crossed with
a well characterized mouse model of mammary tumorigenesis, MMTV-Her2. The tumor initiation
and progression in this strain is driven by overexpression of Her2/ErbB2, a growth factor
receptor of the EGFR family, leading to spontaneous mammary gland tumors and metastasis,
seen in human cancers characterized by Her2 overexpression.
Materials and Methods
Generation of conditional NEDD9 knock IN (Floxed-STOP-NEDD9) transgenic strain and
locus insertion.
A targeting vector was utilized for homologous recombination at the Rosa26 locus of the
murine genome. The insertion portion of the targeting vector contains a CAAG ubiquitously
expressed promoter (CMV immediate early enhancer/ chicken b-actin promoter fusion), coupled
to a start site, followed by a stop codon in frame, flanked by LoxP Cre recombinase recognition
cassettes. Downstream of the LoxP cassette is the coding sequence for NEDD9 (Fig.1A).
Vector design, mouse embryo injection, and transplantation was performed by GenOway, Inc.
into a C57BL/6 background. The PCR screening for homologous recombination at the 5’ end of
the targeting vector was performed using set of designed primers: GX6043/44, generating
1870kb fragment (Fig.1B). Once chimera mice were generated yielding homozygous floxed
NEDD9 knock-in offspring, embryos were cryopreserved and stored at the Jackson Laboratory.
Due to the significant impact of genetic background on tumorigenesis the NEDD9
transgene was transferred to FVB background using speed congenic technology executed by
Charles Rivers Laboratory and WVU Transgenic Animal Facility. The successful transfer of
NEDD9 transgene was confirmed by PCR analysis as outlined below.
Backcrossing strategy
Floxed-STOP-NEDD9 mice were backcrossed from a C57BL/6J background into an
FVB/J strain background via the selection using MaxBax (Charles Rivers) single nucleotide
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polymorphism analysis of the offspring. By comparing unique single nucleotide polymorphisms
possessed by either C57BL/6 or FVB/J we were able to determine which mice to use for further
breeding in order to achieve the greater than 96% of FVB/J mice background still containing the
Cre-NEDD9 knock-in allele. The successful transfer was produced after the 3rd crossing (N3)
with the 98% of transfer to FVB genetic background, resulting in FVB/J-Floxed-STOP-NEDD9.
Similar genotyping protocol as for C57BL/6J was used to confirm the presence of NEDD9
transgene in FVB/J strain (Fig.2A).
Generation of FVB/J-MMTV-Cre-NEDD9+/+ mice for mammary gland specific upregulation
of NEDD9.
The FVB/J-Floxed-STOP-NEDD9 mice were crossed with FVB/J-MMTV-Cre mice
expressing Cre recombinase under the mouse mammary tumor virus (MMTV) promoter, specific
for mammary gland epithelium. This line was obtained via a gracious gift from Dr. J Michael
Ruppert. The resultant offspring were genotyped using set of designed primers to detect wild
type, recombined and Cre-excised allele of NEDD9. Homozygous for NEDD9 insertion FVB/JMMTV-Cre/NEDD9+/+ mice were used for analysis of normal mammary gland development and
for further crosses with mammary tumor models. The upregulation of NEDD9 in mammary
epithelium was confirmed by western blot analysis (Fig. 2C).
Generation of FVB/J-MMTV-Cre-NEDD9+/+-Her2 mice for mammary gland specific
upregulation of NEDD9 and Her2/Erbb2/neu oncogene.
FVB/J-MMTV-Cre/NEDD9+/+ mice were crossed with FVB/J-MMTV-Her2/Erbb2/neu mouse
model for mammary tumors in humans purchased from Jackson Laboratories. This strain
expresses unactivated wild type cDNA of rat Erbb2. The resultant strain expressing all three
transgenes: Cre, NEDD9 and Her2 was confirmed by PCR analysis using target specific primers
as outline in the Genotyping section. This line along with MMTV-Cre, and MMTV-Cre/NEDD9+/+
and MMTV-Her2 are observed for the tumor formation. According to the literature MMTV-Her2
mice start forming tumors at 8 months or older. We expect that overexpression of NEDD9 will
promote tumorigenesis by shortening the tumor initiation period, including earlier tumor cell
invasion and metastasis resulting in a faster growing and more aggressive cancers.
Genotyping
Mouse DNA was isolated from 0.3-0.5cm tail fragment using the PrepEase kit (Affymetrix) as
per manufactures instructions. Mice were genotyped using the following primers: human
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NEDD9

knock-in

allele=

GGGCCTTTTGCTGATGAGGG-3’,

5’-TCCCAGAGTGTGCCGAGGAA-3’/5’-

Rosa26=5’-CAATACCTTTCTGGGAGTTCTCTGC-3’/5’-

CTGCATAAAACCCCAGATGACTACC-3’,
TTTCCTGCAGCAGCCTACGC

and

Her2=5’-CGGAACCCACATCAGGCC

Cre=

-3’/5’-

5’-GGTTCTGATCTGAGCTCTGAGTG-3’/5’-

CATCACTCGTTGCATCGACCG-3’. Using the previously listed primers and PCR Ranger
mixture (Bioline) resulted in the following band sizes, indication the presence of the allele:
NEDD9 knock-in= 553 base pairs, Rosa26= 300 base pairs, and Cre= 900 base pairs, Her2=
600 base pairs (Fig 2A).
Generation of MEFs and knock-in allele test
Mouse embryonic fibroblasts, MEFs, were generated from embryos harvested at day 12
(E12). Sterile technique was used to avoid cross contamination. Collected embryos were
minced using #10 scalpel blades and incubated for 15 minutes in 0.25%Trypsiin/EDTA at 37°C.
Full media, 'XOEHFFR V PRGL¿HG (DJOH V PHGLXP supplemented with 15% fetal bovine serum
and antibiotic-antimycotic, was added to neutralize the trypsin. Cells were pelleted by
centrifugation, re-suspended in full media, plated, and passaged. Cells were cryopreserved for
later use.
In order to test the effectiveness of the transgenic construct, inducible NEDD9 knock-in
MEF cell lines were infected with pre-packaged adenovirus expressing GFP (green fluorescent
protein), Ad-Cre-GFP (Vector Biolabs) as per manufactures instructions. Infection was
monitored through fluorescent microscopy and in 24h reached 100% efficacy based on the GFP
fluorescence when compared to uninfected control. Control and Ad-Cre-GFP infected cells were
lysed and probed by western for NEDD9 and GAPDH protein levels as previously described (Ice
2013) (Fig.2B).
Mammary gland resection and analysis
The fourth inguinal mammary gland was resected and prepared as described in (de
Assis 2010). Briefly, MMTV-Cre recombinase expressing control and MMTV-Cre/NEDD9+/+
knock-in virgin female mice were euthanized at 6 weeks of age and mammary glands resected.
Mammary glands were placed on glass slides and allowed to dry for 10 minutes. Slides were
then places in Carnoy's fixative (75% Acetic acid, 25% ethanol) for two days. Slides were then
rinsed in 70% ethanol for one hour, followed by distilled water for 30 minutes. Mammary glands
were then stained in Carmine Alum stain (0.2% carmine dye, 0.5% aluminum potassium sulfate
in distilled water) for two days. Ethanol washes were then performed for 30 minutes each in
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increasing concentrations of ethanol (70%, 80%, 95%, 100%). Tissue was then allowed to
delipidate in xylene for two days followed by mounting. Whole mounts of mammary glands were
imaged at 4X using an Olympus AZ70 microscope; after which bud to branch ratio was
calculated in 5 mice per group. Statistical software (Graphpad Prism) was used to determine
significance via Students T-test with a p-value of 0.0324.
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Results

Experimental rationale and generation of FVB/J-Floxed-STOP-NEDD9 mice
To determine the role of NEDD9 in tumorigenesis and metastasis in vivo, we
developed a transgenic mouse strain which, when in the presence of Cre recombinase,
overexpresses NEDD9. Since we do not predict abundant NEDD9 to be oncogenic
alone, we crossed our strain with the oncogenic strain MMTV-Her2. The generated mice
containing all three transgenes, Cre, NEDD9, and Her2, will be evaluated for tumor
latency, burden, size, and metastasis. An additional advantage of the Cre inducible
model design is the ability to use the multitude of tissue and time specific Cre
recombinase promoter strains available.
Evaluation of Cre-dependent expression of NEDD9 in FVB/J-Floxed-STOP-NEDD9
Through utilizing mouse embryo fibroblasts generated from FVB/J-Floxed-STOP-NEDD9
mice, we were able to overexpress NEDD9 upon infection with adenoviral Cre recombinase.
Using western blot analysis we detected a robust overexpression of NEDD9 when compared to
uninfected MEFs (Fig. 2B); therefore, indicating the Cre recombinase inducible vector is
functional and producing a NEDD9 product of full length which is recognized by monoclonal
antibody specific to NEDD9. Mammary glands harvested from MMTV-Cre and MMTVCre/NEDD9+/+ indicate that there is indeed an increase in NEDD9 in the mammary fat pad.
NEDD9 overexpression increases mammary gland budding
In order to evaluate if NEDD9 overexpression effects the normal mammary gland
development we assessed the difference in mammary gland branching between MMTV-Cre and
MMTV-Cre/NEDD9 knock-in virgin mice. In order to determine if there is a difference in
mammary development whole mammary gland mounts were prepared from 6 weeks old virgin
mice according to the protocols outlined in material and methods section. We found that upon
NEDD9 overexpression there was an increase in the budding to branch ratio, indicating that
NEDD9 plays a role in mammary gland development (Fig. 3A-B). Overexpression of NEDD9
either increases proliferation and/or invasion of normal mammary epithelial cells or could
potentially predispose to cancer. Further work is needed to validate this phenotype, but it is
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important to take it into account when analyzing the NEDD9 overexpression impact on the
background of Her2 oncogene.

The currently ongoing characterization of FVB/J-MMTV-

+/+

Cre/NEDD9 /Her2 mice will allow us to define the role of NEDD9 in mammary tumorigenesis.
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Discussion
Cre recombinase inducible transgenic mouse model systems provide a versatile tool for
the study of protein in either a tissue or time specific manner. By developing a Cre inducible
human NEDD9 knock-in mouse model system we are able to study the role of overexpressed
NEDD9 in a mammary specific context similar to what is present in breast cancer patient
samples.
The previous studies have investigated the role of NEDD9 in mammary tumorigenesis
(Izumchenko 2009, Little 2012) using NEDD9 knockout mouse model crossed with mammary
specific oncogenic mouse strains, MMTV-PyVmT and MMTV-Her2. While both studies did show
that NEDD9 plays a role in tumor growth, latency, and burden. A major complication of this
strategy is the ability of p130Cas, a protein in the same family as NEDD9, to be induced and
compensate for loss of NEDD9. In this instance the importance of NEDD9 in tumorigenesis
would be difficult to accurately evaluate understate. It is for this reason that we believe our
developed model system more accurately portrays native mammary tumorigenesis.
Both NEDD9 and Her2 are found to be overexpressed in breast cancer, and therefore
make a more clinically relevant model system to study tumorigenesis. By creating this model
system we will be able to study novel anti-metastatic therapies, since NEDD9 has been shown
to be a marker of metastatic disease. Additionally, the inducible nature of our model provides
versatility through crossing it with other tissue and time specific Cre promoter driven mouse
strains. Finally, our model can be helpful for future drug development targeting NEDD9 and
NEDD9-dependent signaling pathways.
Taken together our results illustrate the creation and application of a Cre recombinase
inducible NEDD9 knock-in mouse model. Additionally, we were able to establish using our novel
model system that overexpressing NEDD9 in mouse mammary glands increases mammary
gland development, which could be attributed to the role of NEDD9 in increasing MMP activity
during tumorigenesis (McLaughlin 2013), although more studies need to be performed to prove
this point directly.
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FIGURES:

A

B

Figure 1. Design and expression of Cre inducible nedd9 knock-in. A) Design of Cre
recombinase inducible NEDD9 knock-in vector for homologous recombination at the Rosa26
locus (top). In the presence of Cre recombinase the STOP cassette is resected out of the
genome due to flanking LoxP sites (middle) resulting in CAAG promoter driven NEDD9
expression (bottom) B) PCR test using GX primer set for homologous recombination.
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Figure 2. A )Genotyping results in triplicate indicating the presence of either the Rosa26 loci
or the NEDD9 loci. B) Western blot analysis of lysates of mouse embryo fibroblasts
prepared from nedd9 knock-in mice with and without being infected with adenoviral Cre
recombinase. NEDD9 protein levels are greatly increased and producing full length
transcript upon infection. C) Western blot analysis of mammary tissue taken from Cre-Nedd9
and Cre-WT mice. Levels of NEDD9 protein are increased in the Cre positive mouse.
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Figure 3. NEDD9 overexpression results in increased budding of mammary glands.
A) Top, a representative image taken of a whole mount section of the fourth inguinal
mammary gland of a 6 week old virgin Cre/NEDD9 knock-in mouse. Bottom, a closer view of
a mammary tree. Arrows indicate a bud, branch, and terminal end bud. B) Quantitation of
bud to branch ratio indicating a significant increase in mammary gland development upon
NEDD9 overexpression. The n=5 with a p-value of 0. 0324.
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Study 4: Development of breast cancer patient derived xenograft
mouse model for the testing of AURKA inhibitor sensitivity and
biomarkers.
Ryan Ice and Elena Pugacheva
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Abstract
The ability to mimic tumor development and metastasis in mouse models in vivo is
critical for the development of novel targeted therapies. Unfortunately, genetically engineered
mouse models (GEMs) which produce tumors through the induction of a single oncogene or
elimination of a single tumor suppressor are rarely seen in the human population. Most tumors
are produced through sequential induction/mutation or elimination of multiple genes and
selection through the prolonged period of time. Additionally, models for hormone related
cancers, such as breast and prostate cancer, do not recapitulate the human tumor due to
differences in hormone production/regulation cycles between mouse and human physiology.
Cell line derived xenograft mouse models are also fraught with obstacles, such as:
homogeneity, aberrant mutations due to being grown in culture, and lack of tumor
microenvironment. Often cell line derived xenografts fail to recapitulate patient-specific pattern
of metastatic spread. Due to these limitations, patient derived xenografts have been developed
and are becoming a widely used tool for cancer therapeutic research. In our study we establish
the patient derived breast cancer xenografts (PDBCX). These will be later used to define the
efficacy of AURKA inhibitor (alisertib-MLN8237) in the treatment/or prevention of metastasis to
the local and distant organs and could be used to assess tumor susceptibility and identify
biomarkers of drug response to streamline the eradication of metastases.
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Introduction
Breast cancer remains the most common non-skin cancer among women and is
considered the second leading cause of cancer related mortality in women. The vast majority of
deaths are caused by metastatic disease. Despite significant progress in treatment options, a
cure of metastatic breast cancer remains elusive. Therefore, it is clear that novel treatment
strategies are required to be developed. A focus on invasion and metastasis is important since
as breast cancer advances from regional to metastatic disease survival rates drop from 82
percent to 26 percent (Siegel 2012). Unfortunately, the translation from cancer cell biology to
clinical application has been fraught with peril. One study suggests that as many as 90 percent
of new cancer drugs fail in the clinic (Hait 2010). One such reason for the low rate of success is
the lack of accurate in vivo models of breast cancer. Current models utilize cell lines which have
been selected for proliferation and for the ability to grow on non-physiological surfaces, such as
plastic. Moreover, when breast cancer cell lines are utilized for xenograft injections the tumor
microenvironment does not recapitulate the endogenous tumor microenvironment. The
influence of the tumor microenvironment has become understood and is necessary for accurate
models for inhibitor testing. Under these circumstances, it is understandable that data generated
using such tools may not be directly translatable to clinical applications (Clarke 2009,
Voskoglou-Nomikos 2003).
By developing the ability to engraft tumor tissue taken from patients and engraft
orthotopically into immunocompromised mice we are able to retain both the tumor
heterogeneousness and the surrounding tumor microenvironment of the original tumor.
Previous studies have shown that through the use of patient derived xenograft transplantation
one can more accurately predict the response of patients to various inhibitors, allowing for
multiple treatment regiments to be tested simultaneously (DeRose 2011). Additionally, patient
derived xenografts are able to phenocopy the location of metastasis presented by patients,
while cell line generated tumors do not, illustrating there utility in studying inhibitors that target
metastasis (Press 2008, Carey 2010, Daniel 2009).
Aurora kinase A (AURKA) is a serine/threonine kinase which plays a key role in the
G2/M transition of mitotic cells. AURKA is essential for normal mitotic spindle formation,
centrosome maturation, and subsequent separation. Many cancer types, including breast, were
found to have high levels of AURKA.
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AURKA inhibitors have recently entered Phase III clinical trials for cancer treatment with
favorable pharmacodynamics and pharmacokinetics, and limited toxicities in hematological
cancers. Unfortunately, the average benefit derived from AURKA inhibitors in advanced solid
tumors has been disease stabilization with few documented instances of tumor regression
(Siegel 2012, Hait 2012, Clarke 2009, Voskoglou-Nomikos 2003, DeRose 2011, Press 2008).
Our understanding of the molecular factors influencing sensitivity and resistance to AURKA
inhibitors remains limited. AURKA expression is directly linked to advanced tumor stage and the
occurrence of metastasis (Voskoglou-Nomikos 2003). Interestingly, it was noted that the
disease relapse and the metastatic dissemination was lower in those patients treated with
AURKA inhibitors (alisertib). There is a critical need to determine the efficacy of AURKA
inhibitors in the prevention and/or treatment of metastasis using more physiologically relevant
modes such as patient-derived metastatic tumor xenografts (DeRose 2011). Identification of a
spectra of cancers sensitive to AURKA inhibitors will provide new diagnostic tools to select
patients who will most likely benefit from AURKA inhibitors and new therapies to treat
metastasis. Completion of these studies is expected to provide new critical knowledge regarding
usage of AURKA inhibitors in the treatment of late stage, high risk of metastasis patients.
In our previous study we found the inhibitor MLN8237 (alsertib) is able to inhibit
metastasis in cell line derived orthotopic xenografts and that reducing the levels of NEDD9
enhanced the anti-metastatic effect of MLN8237 (Ice 2013). The goal of this study is to establish
the patient derived breast cancer xenografts (PDBCX) model system and tissue bank to be
used for the future purpose of evaluating the efficacy of anti-metastasis therapies.
Materials and Methods
Patient sample selection for transplantation into mice. The following clinical characteristics
of the patients will be considered at the procurement stage: large tumor size (20>mm), and
stage III and IV with local/distant metastasis confirmed. Samples were either acquired from the
lab of Dr. Alana Welm at the Huntsman Cancer Institute at the Univeristy of Utah or through the
Cooperative Human Tissue Network at the National Cancer Institute. The number of samples
for this study is based on published records and tumor uptake rates. We have collect 13
biopsies for stages III-IV (Table 1). Engraftment of late-stage tumors (stage III-IV) is 40-60%
(DeRose 2011). The NSG mouse strain has demonstrated up to 100% tumor retention and is
considered the best model for human cancer transplantation (Ishikawa 2005). Based on this
evidence we expect at least 60% of collected breast cancer biopsies will be successfully grafted
in NSG mice. We have currently six tumors successfully engrafted.
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Patient Tumor collection and processing
Upon resection, tissue samples were collected and submerged in Dulbecco's Modified Eagle
Medium, (DMEM, Sigma) and stored at 4°C on ice during shipment. Tissue samples were
processed within 24 hours of collection. Upon arrival, samples were divided into approximately
2mm cubed pieces.
Portions of tissue were fixed in Zn based formalin fixative (Fischer Scientific) and
embedded in paraffin for later analysis of stroma profile and immunohistochemical staining.
Portions of the tissue were flash frozen in liquid nitrogen for analysis by western blot using antiNEDD9 2G9, anti-AURKA (Becton Dickinson), and anti-AURKA Thr288 (Cell Signaling) as
previously described (Ice 2013). Remaining tissue specimen pieces were either immediately
transplanted or cryopreserved in 95%serum, 5% dimethyl sulfoxide (Sigma) and stored in liquid
nitrogen.

Engraftment of the Tumor Biopsies in NSG Mice. Breast cancer fragments are obtained from
patients at the time of surgery or biopsy (before neo adjuvant treatment) and grafted into the fat
pad of 4-6 weeks old female NSG mice. Mice are maintained in BSL2, pathogen-free animal
housing at the WVU Animal Facility. Based on our experience, tumors start growing at the graft
site between 2 to 8 weeks after surgery. Each patient derived tumor, upon successful growth in
the mouse, will be isolated and the tumor mass cut into 1x2x2mm (WxHxL) fragments and
transplanted into the mammary fat pad of a new NSG mouse. This procedure is called
passaging of tumor and could be repeated up to 10-15 times to expand the number of animals
bearing the tumor of the same origin. Finally, a portion of the tissue is stored frozen in DMSOfetal bovine serum, freeze-dried in nitrogen for use in further studies, or fixed in PBS/10%
formalin for histopathological analysis.

Histology of xenografts and comparison with original patient tumors. The comparison
between the histology of the original tumors and their xenografts will be established at early and
later passages by a pathologist at WVU’s Pathology Core Facility (Dr. Livengood) using
paraffin-embedded sections and standard imunohistochemistry (IHC) staining protocols, which
are currently under preparation. The histology of the original tumor is usually conserved in
xenografts (DeRose 2011). The morphology of cancer cells and the stroma will be assessed in
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original tumors and in xenografted biopsies by IHC staining with specific epithelial and cell
proliferation markers to confirm the stable propagation of tumor.
Tumor and Estrogen implantation
De-identified tumor tissue samples were obtained under HIPAA guidelines with informed
consent. All procedures and protocols were approved by WVU IACUC and veterinary staff. The
surgical procedure of tumor transplantation and preparation was performed as described in
DeRose et al. (DeRose 2011). Transplantation of tumor tissue was performed using aseptic
technique under sterile conditions. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient
mice (Jackson Laboratory, stock 5557) were anesthetized using isoflurane/oxygen mixture
between 2-0.5%. Prior to surgery bupivacaine and carprofen were administered subcutaneously
for local and general analgesic pain relief respectively. The fourth inguinal mammary gland of
female mice 4 to 6 weeks of age was resected thus removing the mammary tree. Tumor tissue
was inserted in the location of the fourth inguinal mammary gland. An incision was then made
between the scapulae, where an estrogen supplement pellet was placed. 7mm wound clips
were used to close both incision sites. Carprofen was administered once daily for three days.
Mice were monitored for seven days post-surgery until wound clips were removed.
Ultrasound analysis of Tumor growth and angiogenesis.
Following tumor transplantation, tumor size and blood flow was measured via the
Vevo2100 Micro-Ultrasound System. A 40 or 50 mHz transducer was used and a 3-dimensional
image (3D) was acquired with 0.051 mm between images. Blood flow was assessed as the
Doppler signal within the tumor. Using the integrated software, the images were reconstructed
to create a 3D image of the tumor at various time points. Upon establishment of growth rate and
engraftment success, tumors were resected, banked, and cryopreserved for later experiments.
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Results
The rates of successful engraftment of breast cancer tissue
The collected tumor tissue from a patient biopsies and surgical resections were
transplanted into NSG mice. The following categories are currently present in our collection ER
positive, Her2 positive, and triple negative (Table 1).To date we have been able to successfully
grow the following transplanted tumors (PEN_001, PEN_002, PEN_003, PEN_006) which is
30% of engraftment. All successful grafts so far are invasive ductal carcinomas (IDC).The
following tumors were not able to grow PEN_004, PEN_005, even though other labs have
successfully achieved engraftment from these samples after prolonged growth period.
Differences in engraftment rates could be due to others using mesenchymal stem cells to
increase angiogenesis. Also we noticed that tumors from patient undergone neo-adjuvant
chemotherapy had much slower growth rates and were not successfully grafted during 8 weeks
period. To date, no indicator has been established as a marker for engraftment.
Analysis of engrafted tumor growth and passaging.
Tumor volume and growth was monitored using VEVO ultrasound (Figure 1).
Transplanted tumor samples were able to re-establish blood flood and induce angiogenesis as
seen by Doppler ultrasound. Engraftment was achieved in various tumor types including
estrogen receptor positive tumors, which need to be supplemented with estrogen in the form of
slow release estrogen implanted subcutaneously. We have collected so far four tumors that
have successfully engrafted.
Discussion
Even though cell line derived tumor xenografts are of great usefulness due to the easy of
manipulating protein expression and infection with viral vectors, the main caveat of cell line
derived model systems is that they do not accurately replicate a spontaneous tumor. The lack of
heterogeneity and stroma dynamics, together with the fact that cell lines have undergone
selection for fast division and the ability to grow on tissue culture dishes, is a source for
divergence of response between patients and cell line model systems. By utilizing patient tumor
xenografts, which have never been grown in tissue culture, we are able to better replicate the
tumor of a patient. Only by recapitulating the tumor of a patient can xenograft inhibitor studies
accurately predict the response of a patient to therapy.
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Since patient tissue is human and present with foreign antigens immunocompromised
mice must be used in order to avoid rejection of the patient tumor tissue. One hurdle patient
derived xenograft systems still need to overcome is the lack of immune system contribution,
which growing evidence shows is a major contributor for tumor development and metastasis,
such as tumor associated T cells and macrophages; though this can be overcome through
humanization of the immune system of the transplant mouse (Motz 2013).
Despite lacking an immune system to aid in development and metastasis, by utilizing our
developed patient tumor xenograft bank we will be able to probe for markers indicating
metastatic location, growth, and AURKA inhibitor susceptibility. Additionally, we will be able to
gather tumors that metastasize to various locations to test whether AURKA inhibitors can be
used to treat specific sites of metastasis or metastasis in general. Perhaps of even greater
impact is that once gathered, our tumor tissue library can be a resource for future inhibitor
studies once new technologies and inhibitors are developed without the need to recruit patients
for clinical trials.
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Figures:

Figure 1. Successful engraftment of patient derived xenograft tumor. A
Composite of VEVO Ultrasound images taken at four weeks post-surgery of
PEN_003 engraftment. Tumor volume equaled 60.63mm3.
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PDX_ID

PDX
(original)

PEN_001

ID

NAT/
MAL

Diagnosis

Source

Sex

Age

Race

Treat
ment

ER/PR
/Her2

M1131301A9

MAL

IDC

Ohio St

F

81

W

PEN_002

HCI_001

MAL

IDC

Utah

F

N/A

N/A

None

-/-/-

PEN_003

HCI_002

MAL

IDC

Utah

F

N/A

N/A

None

-/-/-

PEN_004

HCI_009

MAL

adenocarcinoma

Utah

F

N/A

N/A

Chemo

-/-/-

PEN_005

HCI_010

MAL

IDC

Utah

F

N/A

N/A

Chemo

-/-/-

PEN_006

M1132001A1

MAL

IDC

Ohio St

F

56

W

PEN_010

M1132321A2

MAL

papillary
carcinoma

Ohio St

F

67

W

PEN_012

ED63092T_003

MAL

IDC

UPenn

F

35

W

Chemo

PEN_014

ED63407T_003

MAL

carcinoma

UPenn

F

58

B

Chemo

PEN_016

ED63423T_004

MAL

IDC

UPenn

F

32

W

None

PEN_018

ED63703T_004

MAL

IDC

UPenn

F

49

W

None

PEN_020

ED62917_T003

MAL

carcinoma

UPenn

F

64

W

None

PEN_021

M1132517A2

MAL

IDC

Ohio St

F

61

W

+/-/-

-/+/-

Table 1. Patient Derived Xenograft Tumor Tissue Received.
Table abbreviations: NAT, normal adjacent to tumor; MAL, malignant; IDC, invasive ductal
carcinoma; Chemo, chemotherapy; F, female
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General Discussion
Collectively, the studies executed in the course of this dissertation work present
multiple novel insights pertaining to the role of NEDD9 in tumorigenesis, metastasis,
and cancer treatment. In Study 1, we demonstrated that NEDD9 protects AURKA from
degradation through blocking CDH1 binding and therefore increasing the amount of
AURKA present in the tumor cell. We were also able to establish that in patient samples
the levels of AURKA and NEDD9 are correlative, indicating that the phenomenon is
present in patient tumors. Additionally, we discovered the major finding that the AURKA
inhibitor MLN8237 (Alisertib) greatly reduced metastasis via two different complimentary
methodologies and that by reducing the levels of NEDD9 we were able to sensitize the
tumor cells thereby virtually eliminating all signs of metastasis. Although the precise
mechanism of action is an area that will need further investigation, these results indicate
a clear clinical use for AURKA inhibitors in treating metastatic disease and the use of
NEDD9 as a biomarker for AURKA inhibitor susceptibility.
Furthermore, the ability of NEDD9 to increase invasion and metastasis in breast
cancer through regulating TIMP2 and therefore MMP14 in Study 2 provides a novel
mechanism for NEDD9 dependent invasion and migration. Although, previous studies
have found NEDD9 to increase invasion and migration via increasing Src and FAK
activity (Law 1996), the addition of yet another mechanism points to the fact that siRNA
based therapies need to be developed to target NEDD9.
In order to investigate the effects of NEDD9 overexpression in the context of in
vivo tumorigenesis we developed a novel inducible mouse line in Study 3. Through our
developing of a Cre recombinase inducible NEDD9 knock-in mouse line, we were able
to investigate the role of NEDD9 in mammary gland development. Illustrating that,
overexpression of NEDD9 leads to an increase in mammary gland bud to branch ratio
indicating enhanced development. Interestingly, mammary gland development has been
shown to be a MMP dependent process, and while it will take more investigation to
prove that the ability of NEDD9 to regulate MMP activity in vivo is indeed the
mechanism of action, it is a promising area for research.
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Lastly, in our striving to better recapitulate human breast cancer we have
developed the capability to utilize the novel method of patient derived xenografts. By
creating a tissue bank of human tissue samples and cataloging tumors which engrafted
we will have an inexhaustible supply of human tissue and at the same time be able to
treat the tumor of a patient with therapies that are not even developed yet. More to our
purpose, we will be able to test the ability of the AURKA inhibitor MLN8237 to treat
metastatic breast cancers which phenocopy the metastatic sites present in patients.
Additionally, we will be able to find biomarkers indicating susceptibility to AURKA
inhibitors without the need of a full clinical trial. Although the influence of an immune
system is a hurdle that needs to be overcome, the development of the patient derived
xenograft system we will be able to more quickly weed out therapies that are ineffective
in human disease, and thusly be able to progress with greater success in clinical trials.
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